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Abstract
Ghrelin is a circulating peptide hormone that plays a regulatory role in many
physiological processes related to energy balance and metabolism. To be recognized by its
receptor, growth hormone secretagogue receptor 1a (GHSR1a), the serine 3 residue of ghrelin
must be octanoylated. This unique posttranslational modification is catalyzed by the enzyme
ghrelin O-acyltransferase (GOAT), a topologically complex integral membrane protein. GOAT
is an intriguing target for biochemical studies, as no other enzyme is known to catalyze
octanoylation of a serine hydroxyl group. It is also an attractive target for diseases related to
ghrelin signaling, such as diabetes and obesity, as blocking GOAT activity would decrease the
levels of acylated (active) ghrelin. However, much about GOAT remains undefined: its catalytic
residues, active site structure, and mechanism are unknown, and assays studying GOAT activity
are limited. The lack of structural and mechanistic information regarding GOAT makes the
rational design of small molecule inhibitors difficult, and the inability to easily apply GOAT
activity assays to a high throughput format has limited the discovery of small molecule GOAT
inhibitors. With these challenges in mind, we have made several improvements to GOAT
activity assays which increase product stability and enable real-time monitoring of ghrelin
acylation. A library screen of small molecules has revealed a novel class of small molecule
inhibitors of human GOAT (hGOAT), which act by covalently modifying a functionally
essential cysteine residue within the enzyme. Finally, mutagenesis studies have revealed several
residues within hGOAT that are required for activity.
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Chapter 1: Introduction

1.1 Protein post-translational modification
Protein biochemistry illustrates the tremendous impact and power of chemical diversity to
construct and control biological systems. The first level of this diversity lies in the amino acid
sequence of a protein, with the twenty common amino acid side chains presenting an array of
chemical functionality. After translation in the ribosome, many proteins undergo post-translational
modifications. These relatively small chemical modifications greatly expand the proteome,
providing alternate structures, localization patterns, protein-protein interactions, and recognition
motifs to proteins with identical amino acid sequences.1
One class of post-translational modification is lipidation, in which a hydrophobic carbon
chain is attached to a protein. This one class of modifications is remarkably diverse, though a
central theme in the role of lipidation is the facilitation of protein-membrane or protein-protein
interactions. Some examples of lipidation include prenylation, GPI-anchor modification, and
acylation. Protein prenylation is the attachment of a 15- or 20-carbon isoprenoid to a cysteine
residue within a C-terminal Ca1a2X motif through an irreversible thioether bond. In the cases of
canonical prenylated proteins such as the GTPase Ras proteins, prenylation drives membrane
localization and protein-protein interactions.2 Glycosylphosphatidylinositol (GPI)-anchored
proteins are modified at their C-terminus by a complex GPI structure, containing a glycan core
consisting of several modified mannose moieties and a phospholipid tail. This lipid modification
enables localization to the plasma membrane, where the protein can carry out a wide range of
physiological processes.3

2
Acylation, the attachment of a carbon chain through an amide, ester, or thioester bond, is
itself still a broad category of post-translational modifications. Two of the most extensively studied
and ubiquitous forms of acylation within the cell are N-myristoylation, the addition of a 14-carbon
acyl chain to the amine of an N-terminal glycine, and S-palmitoylation, the addition of a 16-carbon
acyl chain to a cysteine thiol, both of which typically promote trafficking of proteins to
membranes.4, 5 O-Acylation, the acylation of a serine or threonine hydroxyl, is less common in
proteins than either N- or S-acylation.5 O- and S-acyl modifications are readily reversed through
cleavage of the ester or thioester bonds by esterases and thioesterases.6-8 In the case of Spalmitoylation, this enables dynamic switching between functionally distinct forms of the
proteins.9 The amide bond of N-myristoylation is much more stable, and this modification is
essentially irreversible during a protein’s lifetime.5

1.2 Ghrelin
1.2.1 Discovery
The peptide hormone ghrelin is one of the many lipidated proteins within the eukaryotic
proteome. However, its particular lipid modification is unique as is its role in endocrine signaling.
Ghrelin was discovered in 1999 as the endogenous ligand for growth hormone secretagogue
receptor 1a (GHSR1a).10 During its initial discovery and characterization, synthetic ghrelin,
consisting of the 28 amino acids encoded by its DNA, exhibited a shorter retention time when
analyzed by reverse phase-HPLC compared to natural ghrelin isolated from rat stomach extracts,
indicating that the natural hormone was modified by some hydrophobic moiety.

Mass

spectrometry analysis revealed that ghrelin’s serine 3 hydroxyl was modified by n-octanoyl group.
Acylation at the hydroxyl of serine, threonine, or tyrosine is relatively rare. No other proteins have
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been shown to contain an O-octanoyl serine modification,11 and acylation at the hydroxyl of serine,
threonine, or tyrosine in general is rare. Only a handful of proteins bearing this class of
modification have been identified: the signaling protein Wnt is acylated at a conserved serine
residue by palmitoleic acid,12 histone H4 protein is palmitoylated at a serine residue,13 and two
toxins found in spider venom, d/w-plectotoxin-Pt1a14 and PLTX-II,15 are palmitoylated at a serine
and threonine residue, respectively. Ghrelin’s serine octanoylation modification is absolutely
essential for its ability to bind and activate the GHSR1a receptor,10 even though both the acylated
and unacylated form of the hormone are present in the bloodstream.16
Despite being unable to activate the GHSR1a receptor, researchers have found evidence
that unacylated ghrelin plays a regulatory role of its own.17 As will be discussed below,
administration of unacylated ghrelin has been shown to antagonize several physiological effects
of ghrelin.18-20 However, it does not act as a direct antagonist of ghrelin binding to the GHSR1a
receptor.21

1.2.2 Ghrelin maturation
Ghrelin must undergo a series of post-translational processing steps in order for it to reach
its mature form (Figure 1.1). Ghrelin is first translated as a 117-amino acid precursor hormone,
preproghrelin.10 The N-terminal signal sequence is cleaved co-translationally to yield the 94-amino
acid proghrelin, with co-translational trafficking to the lumen of the endoplasmic reticulum. Here,
proghrelin is octanoylated at its serine 3 residue by the enzyme ghrelin O-acyltransferase
(GOAT)22,23 and is packaged into secretory granules. Proghrelin is subsequently cleaved by
prohormone convertase 1/324 to produce the 28-amino acid mature form of ghrelin, which can then
be released (along with the 28-amino acid unacylated ghrelin) into the bloodstream. Another
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peptide hormone, obestatin, is an alternative cleavage product of proghrelin, consisting of 23
residues within the C-terminus of proghrelin.25

1.2.3 Expression pattern
Ghrelin

is

primarily

expressed

in

the

stomach.10,

26

In

situ

hybridization,

immunohistological staining, and radioimmunoassays identified both acylated and unacylated
forms of ghrelin within distinct endocrine cells in the stomach (X/A-like cells in mice and rats,
P/D1-like cells in humans).27,

28

Significant levels of both forms are found throughout the

gastrointestinal tract, though at lower levels than in the stomach.16, 29, 30 Ghrelin is also produced in
significant levels in pancreatic islets, as determined by immunohistological staining,27 though there
isn’t consensus regarding which type of islet cell(s) express the hormone.31, 32 RT-PCR analyses
have also revealed levels of ghrelin expression in the arcuate nucleus of the hypothalamus in rats
and mice,33 and pituitary tissue of rats and humans,34, 35 both regions which express high levels of
ghrelin’s receptor.36, 37 Low levels of ghrelin expression have also been detected in the other
peripheral tissues such as kidney,38 lung, gall bladder, prostate, and liver.39

5

Figure 1.1 Maturation of ghrelin. Ghrelin is octanoylated at its serine 3 residue in the
endoplasmic reticulum by ghrelin O-acyltransferase and using octanoyl CoA as the acyl donor.

6
GOAT is also most highly expressed in the stomach and pancreas, and significantly but to
a lesser degree downstream of the stomach in the gastrointestinal tract.22, 23 Specifically, in situ
hybridization demonstrated colocalization of GOAT mRNA and ghrelin in the endocrine cells of
the gastric mucosa of the stomach.40 Significant but lower levels of GOAT expression are seen in
the pituitary and hypothalamus, mirroring the hierarchy of ghrelin expression in the same tissues.41

1.2.4 Physiology of ghrelin signaling
Since its discovery, ghrelin has been shown to play a role in many physiological processes,
many of which involve aspects of energy balance and metabolism.

Growth hormone release
As a ligand for the GHSR1a receptor, acylated ghrelin (hereafter referred to as ghrelin)
stimulates release of growth hormone (GH) through an increase in intracellular Ca2+.10 In both rats
and humans, intravenous administration of ghrelin results in an acute increase in GH concentration,
with a peak within 15 minutes after administration and a return to basal levels after 1-2 hours.42, 43
Ghrelin mimetics that activate the GHSR1a pathway have been investigated as potential
therapeutics for age-related declines in physical strength resulting from decreased GH secretion.44,
45

GOAT-knockout mice exhibit decreased GH release,46 leading to lethal hypoglycemia under

starvation conditions.47 However, under normal diet conditions, GOAT-knockout mice display
normal body weight and fat composition,48 and ghrelin-knockout mice do not show growth
abnormalities,49,

50

indicating the ghrelin-growth hormone pathway may be at least partially

redundant with other endocrine mechanisms regulating growth hormone secretion.
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Appetite
Ghrelin is perhaps most well-known for its role in hunger signaling. Ghrelin remains the
only known circulating hormone that increases the hunger sensation and food intake. Ghrelin binds
to GHSR1a in the arcuate nucleus of the hypothalamus, stimulating neuropeptide Y (NPY) and
Agouti-related peptide (AgRP) activity through the AMPK pathway in these neurons which
regulate food intake and satiety.33, 51 Administration of ghrelin results in an increase in food intake
in rats,52, 53 mice,54 and humans55 within minutes of ghrelin infusion. Endogenous ghrelin levels
increase before meals, and decrease immediately after, independent of time- or food-related cues.5658

Fasting induces increased ghrelin expression in the stomach.59

Adiposity, obesity, and response to starvation
Increased food intake resulting from ghrelin activation of the arcuate nucleus can lead,
unsurprisingly, to weight gain. However, increased ghrelin signaling can lead to increases in fat
body mass through the upregulation of genes responsible for de novo lipogenesis in white adipose
tissue, independent of food intake and energy expenditure.60 These increases in body mass are also
independent of GH and of NPY signaling in the hypothalamus, as ghrelin-induced adiposity was
seen in NPY-deficient mice, and administration of GH alone did induce adiposity.54 Ghrelin
induces adiposity through the promotion of fatty acid storage and decreasing lipid metabolism.54,
61

Specific adipogenic effects were seen with continuous infusion of ghrelin or unacylated ghrelin

in bone marrow of GH-deficient rats.62 A recent study discovered evidence for localization of
GOAT within the plasma membrane of mouse bone marrow adipocytes, and that ghrelin-induced
adiposity within bone marrow depended on the presence of GOAT.63 This suggests that in bone
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marrow adipocytes, the target cell mediates its own ghrelin signaling through direct activation of
the hormone.
Ghrelin may play a role in protection from starvation. During severe calorie restriction,
WT mice were able to maintain blood glucose levels, but glucose levels in GOAT knockout mice
decreased to lethal concentrations.47 While under normal conditions ghrelin promotes fat storage,
during starvation, GH release stimulated by ghrelin can increase lipolysis in adipose tissue64 and
decrease the glucose used by muscle, or may directly mediate gluconeogenesis.65
Despite ghrelin’s general positive correlation with food intake and adiposity, obese
subjects exhibit lower levels of plasma ghrelin.66-68 Exogenous ghrelin administration does not
stimulate food intake, growth hormone secretion, or activation of NPY/AgRP in diet-induced
obese mice,69 and obese humans do not exhibit normal ghrelin decreases after meals.70, 71 A
potential exception to this observation is seen in patients with Prader-Willi syndrome. Patients
with this genetic disorder exhibit symptoms such as mild mental retardation, growth hormone
deficiency, short stature, and insatiable appetite (hyperphagia).72, 73 Elevated ghrelin levels have
been observed in cases of Prader-Willi syndrome,74-77 although the mechanism by which ghrelin
affects appetite in these patients has not yet been fully defined.77-79

Insulin regulation
Ghrelin inhibits glucose-stimulated insulin regulation.80, 81 Endogenous ghrelin and insulin
levels are normally inversely correlated throughout the day,57 and exogenous administration of
ghrelin suppresses insulin secretion and increases plasma glucose levels after meals.80, 82
Although unacylated ghrelin does not bind to GHSR1a and was initially thought to be an
inactive ghrelin degradation product, administration of unacylated ghrelin has been found to
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counteract the effects of ghrelin on insulin inhibition.19, 83, 84 This indicates the ratio of ghrelin to
unacylated ghrelin may be an important factor in insulin sensitivity.85 Treatment of neonatal mice
with ghrelin prevented the onset of diabetes,86 and several studies have found that decreased
ghrelin levels are associated with insulin resistance in both type I and type II diabetes in humans.8790

However it is unclear whether this is a direct cause or a compensatory effect.
An inhibitory role for unacylated ghrelin against insulin resistance is supported by the

development of unacylated ghrelin analogs as therapeutics. Administration of AZP531, a cyclized
peptide consisting of ghrelin’s residues 6-13, improves insulin sensitivity in both mice and
humans.91, 92 As this compound lacks ghrelin’s acylated N-terminus, it is not expected to bind to
GHSR1a or GOAT,10, 93, 94 suggesting that unacylated ghrelin and its ghrelin analogs exert their
physiological effects via an undefined mechanism.

Anti-inflammation
Both ghrelin and its receptor are expressed in human T cells, and expression levels of both
increase upon T cell activation.95 Ghrelin was shown to inhibit production of multiple
inflammatory cytokines in these and umbilical vein endothelial cells.95, 96 Increased levels of
circulating ghrelin are seen in patients with both chronic and acute inflammatory diseases such as
bacterial endotoxin-induced inflammation,97 ulcerative colitis,98 and ankylosing spondylitis99 in
response to the inflammation, though lower levels have been seen in rheumatoid arthritis.100

Gastrointestinal motility
Soon after its initial discovery, ghrelin was shown to stimulate gastric acid secretion and
gastrointestinal motility in rats.101 These effects are blocked with either a GHSR1a antagonist or
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anti-NPY antiserum, indicating that these effects are mediated though GHSR1a signaling and NPY
activation.102 Ghrelin appears to act both centrally and peripherally, as its promotility effects
depend both on the vagus nerve102, 103 and cholinergic neurons within the small intestine.104 Low
levels of circulating ghrelin are associated with gastritis.105, 106 Ghrelin administration to rats with
gastroesophageal reflux disease did not increase motility, indicating that ghrelin signaling may be
impaired in some gastrointestinal diseases.107

Learning and memory
In addition to its many roles in energy homeostasis, ghrelin also has been associated with
neurological functions. Ghrelin not only stimulates the physical sensation of hunger as described
above, but also the motivation to seek and work for food through the reward system in the brain,
mediated by the release of dopamine.108-111 Ghrelin has been shown to be important in other rewarddriven behavior, including the use of alcohol,112, 113 nicotine,114-116 and cocaine.117
Through the stimulation of the hippocampus and amygdala, ghrelin also facilitates learning
and memory111 through the promotion of long-term potentiation and increased neuron spine
density.118 It may enhance fear memory, such as that in posttraumatic stress disorder,119 but may
also protect against stress-induced symptoms of depression.120

1.3   Ghrelin O-acyltransferase (GOAT)
1.3.1 Discovery of GOAT
After ghrelin’s discovery in 1999, the enzyme that catalyzes the octanoylation modification
remained unknown until 2008 when it was discovered simultaneously by two independent research
groups.22, 23 Ghrelin O-acyltransferase (GOAT), belongs to the membrane-bound O-acyltransferase
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(MBOAT) superfamily of enzymes. This enzyme family includes two other protein
acyltransferases, hedgehog acyltransferase (Hhat) and Porcupine (PORCN).121, 122 Other MBOAT
enzymes, such as acyl CoA:cholesterol acyltransferases (ACATs)123 and acyl CoA:diacylglycerol
acyltransferase (DGATs)124 modify small molecule substrates.
GOAT is a topologically complex integral membrane protein residing in the ER membrane
and contains 11 transmembrane helices and one reentrant loop as determined by epitope tagging
and selective permeabilization studies (Figure 1.2).125 Surprisingly, this study found that residues
N307 and H338, both of which are proposed to be involved in catalysis, reside on opposite sides
of the membrane. Mutating either of these residues to alanine abrogates activity.22 GOAT’s active
site is proposed to be within its C-terminal half, based on conservation with other MBOAT
enzymes22, 121 and photocrosslinking studies.125 Beyond this, much about GOAT’s structure and
mechanism remain unknown, including specific residues directly involved in substrate binding
and catalysis.
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Figure 1.2 Proposed topology of ghrelin O-acyltransferase within the ER membrane, as
reported by Taylor et. al.125 Green bars represent transmembrane helices, and purple bar
represents a reentrant loop. Functionally essential residues N307 and H338 are shown as yellow
stars. Figure reproduced with permission from Reference 125 (Appendix I) © 2013 American
Society for Biochemistry and Molecular Biology.
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1.3.2 GOAT substrate selectivity and recognition of ghrelin
While the location and nature of the active site and catalytic mechanism of GOAT remain
unknown, functional and structural elements within the ghrelin substrate which are important for
recognition by GOAT have been determined. GOAT efficiently modifies short peptides consisting
of ghrelin’s first five residues (GSSFL-NH2)94, 126 and detectibly modifies substrates consisting of
four residues (GSSF-NH2).126 GOAT exhibits a strong requirement for ghrelin’s glycine 1 (G1)
residue, with selectivity based both on charge and sterics. The mouse isoform of GOAT does not
accept substrates with additional residues N-terminal to G1 of ghrelin.94 Mutations of G1 which
remove charge of the N-terminal amine, introduce steric bulk larger than one methyl group to the
N-terminal amine, or incorporate any side chain are not tolerated.94, 127, 128 Moderate mutations at
ghrelin’s S2 are tolerated in general; GOAT was found to modify a proghrelin substrate containing
an S2A mutation as well as it did WT proghrelin,94 and threonine was also accepted as well as
serine at this position, suggesting the hydroxyl side chain may be recognized.127 There may be
steric and charge requirements at the S2 position, as substrates containing tryptophan, aspartate,
or proline at this position were not reactive.127, 128 GOAT displays a broad tolerance for mutations
of F4, modifying substrates containing a wide range of natural and unnatural amino acids at this
position with reduced but detectable activity,94, 128 with the exceptions of lysine and glutamate
which were completely unreactive.128
GOAT exhibits a strong selectivity for serine at the 3 position, the site of acylation.
Mutation of S3 to alanine results in complete loss of reactivity,22, 94, 127 indicating that GOAT will
not octanoylate S2. Human GOAT will modify a threonine hydroxyl at this position, though less
efficiently.128 There is also evidence that GOAT will acylate an amine in place of the serine 3
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hydroxyl.129 These recognition and reactivity elements within ghrelin’s N-terminus provided
parameters for bioinformatics analysis to confirm that ghrelin is GOAT’s only substrate.128
GOAT can accommodate a range of acyl-donor lengths. In their initial discovery of GOAT,
Gutierrez et. al. transfected HEK293 cells with GOAT and preproghrelin, and supplemented the
media with fatty acids of varying lengths. Through immunoprecipitation and analysis by MALDITOF, they detected ghrelin modified by acyl chains ranging in length from four to fourteen
carbons.23 An in vitro enzymatic assay using microsomal fraction containing GOAT, ghrelin
peptide substrate, and acyl CoA acyl donors of different lengths was used to determine that GOAT
modifies ghrelin with hexanoyl and octanoyl CoA more efficiently than with longer chain fatty
acyl CoAs such as palmitoyl CoA.126 This preference for medium chain fatty acids was also seen
in vivo: when mice fed a diet rich in specific medium chain fatty acids or triglycerides (C6 – C10),
the acyl modification of ghrelin isolated from their stomachs corresponded to the fatty acid
ingested, and this correlation was not seen with ingestion of short chain (C4) or long chain (C16)
fatty acids or triglycerides.130
To determine relative binding affinities of different length acyl chains to GOAT without
additional complicating factors inherent in activity assays using different length acyl donors,
Darling et. al. determined IC50 values for a series of peptide-based product mimetic inhibitors
containing an acyl modification at the third residue linked through a hydrolytically stable amide
bond. The structure-activity profile for this inhibitor series revealed that GOAT binds octanoyl
chains much more strongly than other short or medium chains.128
In the absence of structural information regarding GOAT, these structure-activity
parameters define recognition of both the ghrelin peptide and acyl CoA substrates by the enzyme,
and begin to reveal what GOAT’s active site could look like.128 In addition, by determining which
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functionalities within each substrate are most important for binding to the enzyme, we can
incorporate those functionalities into GOAT inhibitors to maximize potency.

1.4   Efforts towards targeting ghrelin signaling for therapeutic development
1.4.1 Rationale for ghrelin signaling as a therapeutic target
Given ghrelin’s role in diseases like diabetes, Prader-Willi Syndrome, and obesity,
modulating the ghrelin pathway presents an attractive opportunity for the treatment of these
diseases.81, 131-134 There are numerous examples of GHSR1a antagonists and agonists in various
stages of preclinical and clinical development.131, 135, 136 An alternative approach is inhibition of
GOAT-catalyzed acylation of ghrelin, rendering ghrelin unable to bind to and activate GHSR1a.
As ghrelin is GOAT’s only known and predicted substrate,10, 22, 128 this route is expected to have a
reduced probability for off-target effects.
As of 2012, few GOAT inhibitors had been reported in the scientific literature, and of those,
only one was reported to inhibit GOAT in a cellular or organismal context.94, 137, 138 Part of the
difficulty in developing inhibitors lay in the lack of structural and mechanistic information
available about the enzyme, as well as the limitations of assays for studying GOAT activity.

1.4.2 GOAT inhibitors (2008 – 2016)
Acylated ghrelin mimics as GOAT inhibitors
The majority of reported GOAT inhibitors are substrate or product analogs of ghrelin. The
first GOAT inhibitors reported are [Dap3]-ghrelin (1-5) and [Dap3]-ghrelin (1-28), which feature
the first five residues of ghrelin or the entire 28-amino acid sequence, respectively. In these peptide
inhibitors, the serine 3 residue is replaced with (S)-2,3-diaminopropionic acid (Dap) in which the

16
side chain amine of this residue is octanoylated (Figure 1.3a).94 Structure activity analysis of the
acyl group length revealed that an octanoyl chain contributes to binding more strongly than any
other length.128 Both [Dap3]-ghrelin (1-5) and (1-28) inhibit GOAT in an in vitro enzyme assay
with IC50 values of 1 µM and 0.2 µM, respectively. However, as peptides these inhibitors have
limited cell permeability and stability to degradation. Given their structural similarity to ghrelin,
they may also activate GHSR1a, as the first four residues of ghrelin and a nonspecific hydrophobic
group at S3 are sufficient to activate the receptor.93
To explore the potential for developing more cell permeable and biostable analogues of
acylated ghrelin mimetic inhibitors, Zhao and workers developed GOAT inhibitors with triazolelinked acyl chain analogues.139 These inhibitors were based on the GSSFL pentapeptide sequence
present in the previously reported GOAT inhibitors,94 with the incorporation of an azidoalanine at
the third position in place of the serine residue that serves as the acylation site. This substitution
enabled convenient modification of the peptide with a wide range of derivatives at this position
through a copper-catalyzed Huisgen 1,3-dipolar cycloaddition between the azide and a substituted
alkyne. Several derivatives of these peptides inhibited GOAT in an in vitro enzymatic assay, with
the most potent featuring a phenylpropyl triazole modification (Figure 1.3b), inhibiting GOAT
with an IC50 value of 0.7 µM. While these inhibitors face many of the same challenges to
therapeutic viability as the [Dap3]octanoyl-ghrelin inhibitors described above, they establish
tolerance of the ghrelin N-terminus scaffold to chemical modification while maintaining potency.
Thus, further modifications may be made to address the issues of cell permeability and GHSR1a
activation.
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Figure 1.3 Acylated ghrelin mimics act as GOAT inhibitors. (a) Pentapeptide [Dap3]-ghrelin
(1-5)-NH2 mimics the first five residues of ghrelin, with the ester linkage of octanoyl serine 3
replaced by a hydrolytically stable amide bond.94 (b) Phenylpropyl triazole-linked ghrelin
peptide mimics the first five residues of ghrelin, with the ester linkage of octanoyl serine 3
replaced by ta hydrolytically stable triazole formed by a Huisgen 1,3-dipolar cycloaddition
between an azide and alkyne.139
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Lipidated small molecules
In addition to the acylated ghrelin mimetic inhibitors described above, two small molecules
have been reported to inhibit GOAT in an in vitro enzyme assay (Figure 1.4). These structurallyrelated inhibitors were identified from a library screen of small molecules and inhibit GOAT with
IC50 values in the low micromolar range in an enzyme-based assay.138, 140 While these compounds
are more “drug-like” in their overall structure compared to the previously discussed peptide-based
GOAT inhibitors, they have not been reported to be effective in cell-based or animal studies of
GOAT inhibition.

GO-CoA-Tat
Validation of GOAT inhibition as a potential therapeutic avenue came from the
development of GO-CoA-Tat, a bisubstrate analog GOAT inhibitor (Figure 1.5).137 GO-CoA-Tat
features the first ten residues of ghrelin, with an octanoyl coenzyme A analog attached to the third
residue through a hydrolytically stable amide linkage, and an 11-residue HIV Tat-derived peptide
attached to the C-terminus to enable cell permeability. Treatment with GO-CoA-Tat inhibits
ghrelin acylation by GOAT in enzyme- and cell based assays as well as in mice. Administration
of this inhibitor to mice improved glucose tolerance and reduced weight gain induced by high-fat
diet.137 Treatment with GO-CoA-Tat has also demonstrated effectiveness in decreasing food intake
in freely-fed rats141 and in attenuating food intake, food foraging, and food hoarding behavior in
food-deprived Siberian hamsters.142
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Figure 1.4 Structurally related lipidated small molecules as GOAT inhibitors. Compounds were
identified by Garner and Janda through a screen of small molecules.138
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Figure 1.5 Structure of bisubstrate analog GO-CoA-Tat, a GOAT inhibitor that is active in celland animal-based models.137, 141, 142 GO-CoA-Tat mimics the first ten residues of ghrelin, with
a Tat peptide sequence (-YGRKKRRQRRR) appended to the C-terminus through an
aminohexanoate (Ahx) linker to enable cell permeability. The serine 3 residue is replaced with
octanamide Dap, with CoA covalently linked to the octanoate.
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1.5 GOAT activity assays – capabilities and challenges
The lack of potent small molecule GOAT inhibitors prevents the validation of modulating
ghrelin signaling as a therapeutic avenue. However, as the structure of the GOAT active site and
nature of the GOAT catalytic mechanism remain unknown, the rational design of small molecule,
“drug-like” inhibitors is not possible at this point. Screening large libraries of small molecules can
allow identification of inhibitors as hit and lead compounds, but in the case of ghrelin octanoylation
this approach is complicated by the limitations of current GOAT activity assays and the inability
to adapt them to a high-throughput format.
Established assays for measuring ghrelin acylation by GOAT activity have either been cellbased, or have relied on microsomal fraction from cells expressing GOAT as an enzyme source in
vitro.

1.5.1 Cell-based assays for GOAT activity
Several cells lines have been identified to study ghrelin acylation by GOAT. In 2001,
human medullary thyroid carcinomas (human TT cells) were found to produce acyl ghrelin,143 and
several years later, Gutierrez et. al. used this cell line to identify GOAT as the acyltransferase that
modifies ghrelin.23 While levels of acyl ghrelin detected from these cells were low, supplementing
the media with octanoic acid increased the amount detected by mass spectrometry.23 Both acylated
and unacylated forms of ghrelin were identified in a human erythroleukemia (HEL) cell line.
Remarkably, ~90% of the ghrelin detected in the cells and in the media was acylated. Yang et. al.22
transfected preproghrelin and candidate acyltransferases into rat insulinoma INS-1 cells to identify
GOAT as the ghrelin acyltransferase, detecting acylated ghrelin by peptide separation on HPLC
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followed by SDS-PAGE and immunoblotting with an anti-ghrelin antibody. They then used this
cell line to transfect mutant forms of GOAT to identify functionally required residues.22
In 2010, Iwakura et. al. established a novel cell line, MGN3-1, isolated from the gastric
tumor of a mouse.145 These cells produced ~140-fold more total ghrelin and ~5,000-fold more
acylated ghrelin compared to TT cells, as measured by N-terminal and C-terminal ghrelin
radioimmunoassay. Zhao et. al. established the PG1 and SG1 cell lines from pancreatic and
stomach tumors, respectively, of mice.146 When PG1 cells were incubated with octanoic acid,
significant levels of acylated ghrelin was detected in both the cells and in the medium, indicating
that ghrelin was not only being produced but secreted as well. SG1 cells were used to determine
that an analog of unacylated ghrelin inhibited secretion of acyl ghrelin.147 Ghrelin and GOAT were
also found to be expressed in cell lines derived from prostate cancer tissues (PC3 cells).148, 149
Ghrelin (at concentrations up to 5 nM) increases PC3 cell proliferation by ~33%, providing a
possible readout for the levels of ghrelin produced.148 Treatment with ghrelin, but not unacylated
ghrelin, downregulated expression of GOAT in these cells, which may complicate studies of
GOAT activity.149
Both HeLa and HEK cell lines have also been used to study GOAT activity. Both have
been stably transfected with genes for the human isoform of the ghrelin precursor preproghrelin
and the mouse isoform of GOAT (mGOAT).137 When supplemented with octanoic acid, acyl
proghrelin is produced, and levels of both acyl and unacylated ghrelin can subsequently be
quantified using an enzyme-linked immunosorbent assay (ELISA).
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1.5.2 Microsomal assays employing radiography
GOAT activity can be measured in in vitro assays using microsomal fraction from
mammalian or insect cells expressing recombinant GOAT. The first such microsomal assay was
reported by Yang and coworkers,94 in which baculovirus containing the gene for mouse GOAT
(mGOAT) was utilized to express mGOAT in Sf9 insect cells. The crude microsomal protein
fraction containing mGOAT was enriched through fractional ultracentrifugation, with this
microsomal protein fraction shown to acylate purified proghrelin when incubated with
radioactively labeled octanoyl CoA. Octanoylated proghrelin was detected by isolating proghrelin
from the reaction mixture by affinity binding to a nickel resin using a C-terminal His8 tag appended
to proghrelin followed by scintillation counting of 3H-labeled octanoate.
Barnett et. al. developed a variation of this assay, using microsomal fraction isolated from
HEK293 cells and ghrelin(1-27) bearing a C-terminal biotin modification, with acylated ghrelin
detected by scintillation counting of 3H-labeled octanoate following streptavidin-pulldown of
ghrelin peptides.137 Subsequent studies reported by this group used microsomal fraction isolated
from insect cells.125, 129
Ohgusu et. al. developed an in vitro GOAT activity assay employing microsomal fraction
isolated from CHO cells expressing GOAT as the enzyme source and unacylated ghrelin and
octanoyl CoA substrates. After incubation of all reaction components, acylated and total ghrelin
were separated by RP-HPLC. Each fraction was analyzed by ELISA or radioimmunoassay, using
anti-ghrelin(1-11) antiserum to detect octanoyl ghrelin, and anti-ghrelin(13-28) to detect total
ghrelin.126
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1.5.3 Cat-ELCCA
Garner and Janda140 developed a GOAT activity assay using an enzyme-linked clickchemistry assay (cat-ELCCA) (Figure 1.6). In this assay, the first five amino acids of ghrelin
(GSSFL) were immobilized on a streptavidin-coated plate using a C-terminal biotin group.
Microsomal fraction containing mGOAT and octynoyl CoA were incubated in the plate, leading
to acylation of the immobilized ghrelin peptide. Following GOAT-catalyzed octynoylation, azidelabeled horseradish peroxidase (HRP) was conjugated to the product via a copper-catalyzed
Huisgen cycloaddition. The ghrelin-HRP conjugate could then be detected using a fluorogenic
substrate which is activated in the presence of HRP and hydrogen peroxide. This assay enabled
the discovery of two lipidated small molecule inhibitors of GOAT through a screen of a small
library of compounds (Figure 1.4).138
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Figure 1.6 Cat-ELCCA format for measuring GOAT activity, as reported by Garner and
Janda.140 An N-terminal ghrelin peptide is immobilized onto a streptavidin-coated plate, and is
modified by octynoate in the presence of GOAT. The alkyne of acylated ghrelin enables
conjugation of an azide-functionalized horseradish peroxidase (HRP), which allows for
activation of a profluorecent substrate in the presence of hydrogen peroxide. Figure reproduced
with permission from reference 140 (Appendix II). © 2010 John Wiley and Sons, Inc.
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1.5.4 GOAT activity assays employing fluorescently labeled peptides
To enable structure-activity analysis of ghrelin recognition by GOAT, our research group
developed a microsomal GOAT activity assay using a fluorescently-labeled ghrelin peptide
substrate.127 A five-residue peptide based on the N-terminus of ghrelin was appended with a Cterminal cysteine (GSSFLC), which could be modified by acrylodan, a thiol-reactive fluorophore.
After incubation with octanoyl CoA and microsomal fraction from insect cells infected with human
GOAT (hGOAT) baculovirus, the fluorescent peptide is octanoylated. In contrast to previously
reported GOAT assays, in which the detected label is on the acyl donor, the fluorophore being on
the peptide substrate enables the simultaneous detection of both the unacylated and acylated forms
of the peptide through their separation by reverse phase-HPLC while monitoring fluorescence of
acrylodan. Octanoylation of the substrate increases its hydrophobicity, resulting in an increase in
retention time.
Each of these reported in vitro assays has been limited by low levels of product conversion,
often less than one percent of the total ghrelin/proghrelin substrate.94, 125-127 It has been proposed
that thioesterases within the microsomal protein fraction used for these assays have been at least
partly responsible for this lack of reaction completion. To ameliorate these effects, many of the
microsomal assays described above include long chain fatty acyl CoAs such as palmitoyl CoA.
These long chain fatty acyl CoAs, which are not themselves substrates for GOAT-catalyzed
acylation of ghrelin,126, 130 compete for these contaminating thioesterases and limit the hydrolysis
of octanoyl CoA, to varying degrees of success.94, 127, 140 However, these assays are still limited in
their ability to study GOAT activity, with conversion rates ranging between <1% to 10%, and
endpoints reached within 5 minutes to 1 hour.
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1.6   Goals of this work
The ever-growing number of physiological pathways in which ghrelin is reported to be
involved necessitates thorough characterization of the enzyme that catalyzes its acylation. Without
the ability to purify GOAT in its active form, the determination of its structure and mechanism
remains elusive, which in turn limits the rational design of inhibitors. Despite these limitations,
screening for inhibitors using our current assay is still a reasonable path toward the discovery of
novel small molecule GOAT inhibitors, and valuable information about functionally essential
residues within GOAT can be determined through site-directed mutagenesis.
Chapter 2 describes the application of alkylfluorophosphonate esterase inhibitors to in vitro
GOAT activity assays to protect against product degradation. This development improves product
conversion and the dynamic range of GOAT assays. In Chapter 3, the discovery of a new class of
hGOAT inhibitors through a library screen of small molecules is described. Structure activity
analysis of these inhibitors reveals they act through alkylation of a functionally required cysteine
within hGOAT. Chapter 4 describes mutagenesis analysis of hGOAT, through which several
functionally required residues within the enzyme are identified. A new assay based on fluorescence
enhancement of a ghrelin substrate upon acylation is described in Chapter 5. This new assay is
amenable to a high-throughput format, and it is applied to a primary screen of a small molecule
library. These studies will further our understanding of how GOAT octanoylates ghrelin, and will
progress the development of small molecule inhibitors of GOAT, which may lead toward
therapeutics targeting ghrelin signaling.
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Chapter 2: Ghrelin octanoylation is completely stabilized in biological samples by alkyl
fluorophosphonates
Portions of this chapter have been previously published and reprinted with permission from
reference 1: McGovern-Gooch, K. R. Rodrigues, T., Darling, J. E., Sieburg, M. A., Abizaid, A.
and Hougland, J. L. (2016), Ghrelin octanoylation is completely stabilized in biological samples
by alkyl fluorophosphonates. Endocrinology, 157(11):4330-4338. Copyright 2016, Oxford
University Press. T. Rodrigues performed experiments investigating ghrelin hydrolysis in rat
blood. M. A. Sieburg performed experiments investigating ghrelin hydrolysis in HEK293FT cell
lysate and MAFP compatibility with ELISA measurements of acyl ghrelin.
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2.1 Introduction
The nature of GOAT as an integral membrane protein has prevented its purification or
solubilization while maintaining enzyme activity. Thus, in vitro assays have relied on membrane
protein fraction enriched from insect or mammalian cells expressing GOAT, as described in the
previous chapter. Each of these assays, including the assay developed by our lab, have suffered
from low levels of product conversion and incomplete endpoints.2-5
One possible explanation for the low endpoints observed is that octanoyl CoA is cleaved
by thioesterases within the microsomal fraction. When measuring the amount of [3H]octanoate
generated from [3H]octanoyl CoA when incubated with microsomal fraction, Yang et. al. found
nearly all of the octanoyl CoA was hydrolyzed within 5 minutes.2 In the presence of palmitoyl
CoA, the majority of the octanoyl CoA was protected, indicating the long chain fatty acids compete
for these thioesterases. Therefore, some GOAT activity assays incorporate palmitoyl CoA to limit
the degradation of octanoyl CoA and increase octanoylated ghrelin product formation.2, 4, 6-8 While
this modification improved the observed octanoyl ghrelin formed in these reactions, the levels of
product detected in these assays were still low (<1-10%). Assays that use higher concentrations of
the octanoyl CoA acyl donor do not benefit from addition of palmitoyl CoA.5
Another possible explanation for the low levels of product conversion is the hydrolysis of
the serine ester of the acyl ghrelin product itself. In biological studies, the ester linkage on serine
3 of acyl ghrelin has been shown to be susceptible to esterase-catalyzed hydrolysis within serum,
tissue homogenates, and cell lysate,9-14 and multiple esterases have been identified as able to
hydrolyze ghrelin in vitro.14-17 These studies demonstrate the esterase activity must be deactivated
either by acidification or protease/esterase inhibitor treatment to stabilize acyl ghrelin for detection
when collecting samples.9-11, 15, 16, 18, 19 The ester linkage of the acyl peptide product in in vitro
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assays may also be susceptible to contaminating esterases in the microsomal fraction (Figure 2.1),
similar to the contaminating thioesterases responsible for hydrolyzing the acyl donor.2
To enhance the levels of acyl ghrelin product generated in our GOAT activity assay, the
ability of potential esterase inhibitors to block product degradation was examined. Alkyl
fluorophosphonates were found to inhibit esterases within microsomal protein fraction, cell lysate,
and blood plasma, preventing the hydrolysis of the octanoyl modification. Incorporation of these
esterase inhibitors enables the more accurate determination of GOAT activity in vitro and of true
concentrations of acyl and unacylated ghrelin in vivo.
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Figure 2.1 Proposed pathways for ghrelin deacylation in circulation and GOAT activity assays.
Ghrelin in circulation is converted to unacylated ghrelin by serum esterase activity; esterase
activity in microsomal protein preparation could lead to peptide deacylation after hGOATcatalyzed octanoylation of a ghrelin mimetic peptide substrate. Reprinted with permission from
reference 1. © 2016, Oxford University Press.
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2.2 Results
Alkyl fluorophosphonate treatment increases the extent of ghrelin peptide octanoylation
Several potential esterase inhibitors were initially tested in our hGOAT activity assay. Both
sulfonyl fluoride and fluorophosphonate-based compounds have been used to suppress ghrelin
deacylation during sample work-up from biological sources.9, 10, 15, 19 To test the ability of these
classes of compounds to protect acyl ghrelin in the new context of a microsomal fraction-based
GOAT activity assay, human GOAT (hGOAT)-containing microsomal fraction was preincubated
with 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), hexadecyl fluorophosphonate (HDFP),
or methoxy arachidonyl fluorophosphonate (MAFP) (Figure 2.2a) at 1 and 5 µM before initiating
the octanoylation reaction with octanoyl CoA and fluorescently-labeled ghrelin peptide substrate,
GSSFLCAcDan. These reactions were incubated at room temperature for 3 hours, well beyond our
previously observed reaction endpoint of 1 hour.5 At this point in our standard assay, reduced
concentration of octanoylated GSSFLCAcDan product is observed, potentially reflecting the
deacylation by esterases outpacing the GOAT-catalyzed acylation in our proposed model. (Figure
2.1)
Relative to the vehicle control, addition of water-soluble sulfonyl fluoride AEBSF neither
increased nor decreased the amount of observed octanoylated peptide. However, inclusion of either
of the alkyl fluorophosphonate compounds, HDFP and MAFP, yielded a ~2-fold increase in the
amount of acylated peptide compared to the DMSO-only control. (Figure 2.2b) The selectivity for
enhancement by alkyl fluorophosphonates supports a model whereby deacylation of the ghrelin
peptide is catalyzed by a membrane associated esterase or thioesterase.20
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Figure 2.2 Alkyl fluorophosphonate inhibitor incorporation increases the yield of acylated
peptide product in an in vitro GOAT acylation assay. (a) Structures of potential esterase
inhibitors AEBSF, HDFP, and MAFP. (b) Treatment with the alkyl fluorophosphonate
inhibitors HDFP and MAFP lead to increased levels of octanoylated peptide substrate after 3
hours of reaction, compared with the vehicle alone (not shown). Treatment with AEBSF did
not yield increased product concentration compared with the vehicle control. (c) Time
dependence of GSSFLCAcDan octanoylation in the presence and absence of MAFP. Open circles,
treatment with DMSO (vehicle); filled squares, treatment with 1 µM MAFP; filled circles,
treatment with 5 µM MAFP. Errors represent the standard deviation from a minimum of 3
independent trials. (b) and (c) reprinted with permission from reference 1. © 2016, Oxford
University Press.
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To further characterize fluorophosphonate-mediated enhancement of ghrelin acylation, we
examined the time-course of the hGOAT reaction in the presence of MAFP. (Figure 2.2c) In the
absence of fluorophosphonate, the level of acyl ghrelin peptide fluorescence reaches a maximum
of ~15% (relative to the total peptide fluorescence) around 90 minutes before decreasing to almost
zero. In contrast, in the presence of MAFP, ghrelin peptide fluorescence continued to increase
before reaching a maximum of ~40% of total peptide fluorescence after 3 hours and leveling off.
The apparent velocity of both the untreated and MAFP-treated reactions is similar at early time
points, indicating that the fluorophosphonates enhance product formation through protection of
the acyl product, rather than a direct stimulation of GOAT activity. That fluorophosphonates do
not directly affect GOAT means that they are completely compatible with GOAT activity assays.

MAFP protects the acylated ghrelin peptide product through esterase inhibition
To confirm the mechanism for the MAFP-mediated enhancement of ghrelin acylation in
the GOAT enzyme assay described above, the hydrolysis of the octanoylated ghrelin peptide and
protection from hydrolysis by MAFP was examined. Octanoylated ghrelin peptide was generated
through a preparative-scale hGOAT reaction in the presence of MAFP to enhance product
formation, followed by product purification by reverse phase HPLC.5 This octanoylated ghrelin
peptide was then incubated with hGOAT-containing microsomal fraction treated with either
MAFP or DMSO vehicle without the addition of octanoyl CoA. Thus, esterases present in the
microsomal fraction would deacylate the peptide, but no GOAT-catalyzed acylation of the peptide
would occur.
In the presence of untreated microsomal fraction, the octanoylated peptide was rapidly
deacylated within 15 minutes and was almost completely deacylated after 1 hour. (Figure 2.3) In
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the presence of MAFP-treated microsomal fraction, the octanoylated peptide was completely
protected from hydrolysis and was stable over 5 hours of incubation. This protection of the acylated
peptide is consistent with concomitant esterases within the microsomal fraction being responsible
for the low levels of product formation seen in standard assays.

MAFP may protect octanoyl CoA from thioesterase-catalyzed hydrolysis
Many reported GOAT activity assays incorporate palmitoyl CoA, which is proposed to
increase concentrations of the octanoylated product generated by competing for thioesterases
within the microsomal fraction which might otherwise consume the octanoyl CoA substrate.2, 4, 68

In the original development of our group’s microsomal assay, a titration of octanoyl CoA revealed

maximum octanoylation activity at a concentration of 500 µM octanoyl CoA.5 The large excess of
octanoyl CoA may have served the same purpose as the palmitoyl CoA used in other assays, acting
as both substrate for the nonspecific thioesterases and for GOAT-catalyzed acylation of the ghrelin
peptide.
We hypothesized that MAFP may inhibit thioesterases within the microsomal fraction, and
that in the presence of MAFP, our assay would no longer require such a large excess of octanoyl
CoA. A titration of octanoyl CoA in the presence of 1 µM MAFP revealed maximum octanoylation
activity at 125 µM octanoyl CoA (Figure 2.4). A fit of the titration curve revealed a Km of 36 ± 15
µM for octanoyl CoA, which is lower than the apparent Km for octanoyl CoA in the absence of
MAFP.5

59

Figure 2.3 Octanoylated ghrelin mimetic peptide is protected from deacylation in the presence
of MAFP. (a) HPLC chromatograms of octanoyl GSSFLCAcDan incubated with microsomal
protein fraction pretreated with 5 µM MAFP. Top trace, 0 min incubation; bottom trace, 60 min
incubation. (b) HPLC chromatograms of octanoyl GSSFLCAcDan incubated with microsomal
protein fraction pretreated with DMSO (vehicle). Top trace, 0 min incubation; bottom trace, 60
min incubation. (c) Time dependence of octanoyl-GSSFLCAcDan deacylation. Filled bar,
microsomal protein fraction pretreated with 5 µM MAFP; open bar, microsomal protein
fraction pretreated with DMSO (vehicle). Octanoylated peptide fluorescence is reported as the
percentage of total peptide fluorescence (octanoyl GSSFLCAcDan and unacylated GSSFLCAcDan).
Error bars represent the standard deviation from a minimum of 3 independent trials. Reprinted
with permission from reference 1. © 2016, Oxford University Press.
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Figure 2.4 Dependence of ghrelin peptide octanoylation on concentration of octanoyl CoA in
the presence of MAFP. Reactions were performed and analyzed as described in the Materials
and methods section. Error bars represent the standard deviation from 3 independent trials.
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MAFP treatment is compatible with ELISA measurements of acyl ghrelin concentrations
Most studies involving measurements of acyl ghrelin in biological samples rely on
commercially available ELISA kits, which typically detect ghrelin with antibodies recognizing
either the N- or C-terminus of the peptide.6, 10, 12, 19 Standard curves for acyl ghrelin were generated
in the presence and absence of MAFP to determine the compatibility of MAFP treatment with
ELISA. Treatment with either 1 or 5 µM MAFP leads to a ~30% increase of the ELISA signal
compared with buffer alone (Figure 2.5). This enhancement is consistent across the range of 100to 2000-pg/ml acyl ghrelin recommended for the ELISA kit. Incorporation of MAFP into
biological samples to stabilize acyl ghrelin from hydrolysis during sample workup is compatible
with measurement of ghrelin by ELISA, as long as the standard curve is generated in the presence
of MAFP as well.
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Figure 2.5 MAFP treatment is compatible with acyl ghrelin measurement by ELISA. (a)
Standard curves generated by serial dilution of acyl ghrelin standards provided with a
commercial acyl ghrelin ELISA kit (Millipore). Standard curves were measured in the presence
of the DMSO vehicle alone (closed triangles) or after ELISA buffer treatment with either 1 µM
MAFP (open squares) or 5 µM MAFP (open circles). Measured acyl ghrelin concentrations
were calculated for each condition using the standard curve generated in the presence of DMSO
alone. (b) Comparison of acyl ghrelin ELISA signal in the presence and absence of MAFP. For
each predicted ghrelin concentration, the signal in the presence of MAFP (1 µM, open squares,
5 µM open circles) was normalized to the signal with the DMSO vehicle alone. Reprinted with
permission from reference 1. © 2016, Oxford University Press.
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MAFP treatment provides protection of acylated ghrelin in biological samples
The ability of MAFP to block acyl ghrelin hydrolysis in biological samples was assessed
in collaboration with the Abizaid lab of Carleton University. The percentage of exogenous acylated
ghrelin that is protected by MAFP treatment of HEK293FT cell lysate and of rat blood plasma was
determined by ELISA. To ensure that MAFP does not affect acyl ghrelin levels detected in the
absence of possible esterase activity, equal amounts of exogenous acylated ghrelin was added to
mock samples composed of lysis or ELISA assay buffer in the presence or absence of MAFP.
MAFP treatment does not markedly increase ghrelin levels compared with untreated controls in
these samples (Figure 2.6, a and b, lanes 2 and 3). In untreated HEK293FT cell lysate, ghrelin is
efficiently deacylated to background levels, whereas MAFP-treated lysate yielded complete
protection of acyl ghrelin compared to buffer controls (Figure 2.6a, lanes 6 and 7). Similar results
were seen in rat blood plasma, which was stored overnight at 4 °C to deplete endogenous ghrelin
before treatment with MAFP or vehicle. Plasma treated with MAFP yielded nearly complete
protection of exogenously added ghrelin, whereas ghrelin added to untreated plasma was nearly
completely degraded (Figure 2.6b, lanes 6 and 7).
MAFP was also shown to be effective at protecting endogenous acyl ghrelin in rat blood
samples. When added directly to the blood samples, MAFP treatment resulted in higher
concentrations of acyl ghrelin detected compared to untreated samples, as well as samples treated
with either AEBSF or HCl (Figure 2.6c), which are the current standard conditions for ghrelin
stabilization.9, 10, 12, 21
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Figure 2.6 MAFP treatment completely protects octanoylated ghrelin from deacylation by
mammalian cellular and blood esterases. (a) Protection of exogenous acyl ghrelin from esterase
hydrolysis in human cell lysate. Acyl ghrelin concentrations are normalized to ELISA buffer
treated with ghrelin alone. Lane 1, lysis buffer treated with MAFP; lane 2, lysis buffer treated
with ghrelin; lane 3, lysis buffer treated with both MAFP and ghrelin; lane 4, untreated cell
lysate; lane 5, cell lysate treated with MAFP; lane 6, cell lysate treated with ghrelin; lane 7, cell
lysate treated with both MAFP and ghrelin. Error bars represent the standard deviation from at
least 3 trials. (b) Protection of exogenous acyl ghrelin from esterase hydrolysis in rat blood
plasma. Acyl ghrelin concentrations are normalized to ELISA buffer treated with ghrelin alone.
Lane 1, ELISA buffer treated with MAFP; lane 2, ELISA buffer treated with ghrelin; lane 3,
ELISA buffer treated with both MAFP and ghrelin; lane 4, untreated plasma; lane 5, plasma
treated with MAFP; lane 6, plasma treated with ghrelin; lane 7, plasma treated with both MAFP
and ghrelin. Error bars represent the standard error from a minimum of 4 biological replicates.
*, acyl ghrelin not detectable by ELISA. (c) Protection of endogenous octanoylated ghrelin in
rat blood samples. Blood samples were acidified by addition of HCl, treated with AEBSF or
MAFP inhibitors, or left untreated before plasma separation by centrifugation. Acyl ghrelin
concentrations were measured immediately after centrifugation (crosshatched bar) or after
plasma incubation on ice for 2 hours (solid bar). Reprinted with permission from reference 1.
© 2016, Oxford University Press.
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2.3 Discussion and conclusions
Ghrelin’s susceptibility to deacylation by esterases has posed a major problem to the study
of the hormone. During the early years following its discovery, concentrations of unacylated
ghrelin in circulation were estimated to be much higher than those of acylated ghrelin.22-24 As
improved methods for stabilizing ghrelin from degradation in biological samples were reported, it
became apparent that the ratio of unacylated to acylated ghrelin may actually favor the acylated
form.19 As unacylated ghrelin exerts biological effects,25-30 accurate measurement of true
circulating levels of each form of the hormone is of paramount importance. While acidification
with HCl or treatment with protease inhibitors such as AEBSF offer some protection of the
octanoyl modification by esterases within biological samples,9, 10, 12, 21 the studies described above
demonstrate that these treatments may not provide complete protection from hydrolysis. On the
other hand, treatment with MAFP completely protects acylated ghrelin from deacylation in both
HEK293FT cell lysate and rat blood plasma.
In vitro studies of GOAT activity also benefit from fluorophosphonate treatment.
Concomitant esterases within the microsomal protein fraction enriched from cells expressing
GOAT degrade the acyl product as it is formed, resulting in low levels of product formation and
endpoints reached within 5 minutes to 1 hour, depending on the specific assay used. This limitation
has hampered the study of GOAT activity. By inhibiting esterases present in the microsomal
fraction used in these assays, the acylated product is protected from degradation, allowing for
greater product accumulation and longer reaction times. Increasing the observed product formation
and reaction times may enable the study of GOAT enzyme variants or ghrelin substrate variants
with lower intrinsic reactivity. MAFP may also protect the acyl donor from hydrolysis catalyzed
by thioesterases within the microsomal fraction, removing the need for large excess of octanoyl
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CoA in our assay. Incorporation of MAFP in other microsomal GOAT assays may also render the
addition of palmitoyl CoA unnecessary.2, 4, 7, 8
MAFP is a broad-spectrum esterase inhibitor, protecting ghrelin deacylation from both
membrane-associated and soluble esterases. Its use should be applicable to all studies investigating
the concentration of ghrelin in vivo, in cellular assays, and in in vitro GOAT activity assays.
Comparison of endogenous acyl ghrelin concentrations in rat blood plasma treated with MAFP to
those treated with either HCl or AEBSF indicate that the ratio of acylated to unacylated ghrelin
may be much higher than previously estimated.19 Given the physiological importance of both
acylated and unacylated ghrelin, incorporation of effective esterase inhibitors such as MAFP or
HDFP is necessary for the accurate determination of the true in situ ratio of the two forms of this
hormone.
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2.4 Materials and methods
General methods
Data plotting and curve fitting were performed with Kaleidagraph (Synergy Software). 4(2-aminoethyl)benzenefulfonyl fluoride hydrochloride (AEBSF) was purchased from Cayman
Chemical and solubilized in water immediately before use. Methoxy arachidonyl
fluorophosphonate (MAFP) was purchased from Cayman Chemical as a stock in methyl acetate
and diluted into dimethyl sulfoxide (DMSO) before use. Hexadecyl fluorophosphonate (HDFP)
was generously provided by the Martin laboratory (Department of Chemistry, University of
Michigan) and diluted into DMSO before use. Octanoyl CoA was solubilized to 5 mM in 10 mM
Tris-HCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored at -80 °C.
Acrylodan (Anaspec) was solubilized in acetonitrile, with the concentration determined by
absorbance at 393 nm on dilution into methanol (e = 18,483 M-1 cm-1 per manufacturer’s data
sheet). The GSSFLCNH2 peptide for fluorescent labeling with acrylodan was synthesized by
Sigma-Genosys in the Pep-screen format, and solubilized in 1:1 acetonitrile:H2O and stored at -80
°C. Peptide concentration was determined by absorbance at 412 nm following reaction of the
cysteine thiol with 5,5’-dithiobis(2-nitrobenzoic acid) using e = 14,150 M-1 cm-1.31

Expression and enrichment of human GOAT (hGOAT)
A gene encoding hGOAT with a C-terminal triple tag (FLAG, HA, His6) was cloned into
the pFastBacDual vector (Invitrogen) using EcoRI and XbaI restriction sites, with the resulting
vector used to produce the baculovirus expression system protocol (Invitrogen). Sf9 insect cells
(5.0 x 108 cells in a 500 mL total culture volume) were infected with hGOAT baculovirus at a
multiplicity of infection of 10 followed by protein expression for 40 hr at 28 °C shaking 150 rpm.
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Cells were harvested by centrifugation (500 x g, 5 min), and freezing the pellet at -80 °C. The cell
pellets were thawed on ice, resuspended in 25 mL lysis buffer [150 mM NaCl, 50 mM Tris-HCl
(pH 7.0), 1 mM sodium ethylenediamine tetraacetate (NaEDTA), 1 mM dithiothreitol (DTT),
complete protease inhibitor (Roche), 10 µg/mL pepstatin A, and 100 µM bis(4nitrophenyl)phosphate]. The resuspended cells were lysed with a Dounce homogenizer on ice,
followed by removal of cell debris by centrifugation (3,000 x g, 4 °C, 10 min). The microsomal
fraction was then isolated by ultracentrifugation of the supernatant (100,000 x g, 4 °C, 1 hr). The
isolated microsomal fraction pellet was resuspended in 50 mM HEPES (pH 7.0) and stored in lowadhesion microcentrifuge tubes at -80 °C until use.

Peptide substrate fluorescent labeling
GSSFLCNH2 (300 µM) and acrylodan (500 µM) were dissolved in 500 µL 1:1 50 mM
HEPES buffer (pH 7.8):acetonitrile, followed by incubation at room temperature in the dark for
18 hr with shaking. Acrylodan-labeled peptide was purified by reverse phase HPLC (Zorbax
Eclipse XDB column, 9.4 x 250 mm) using an isocratic mobile phase of water containing 0.05%
trifluoroacetic acid (TFA) (65%) and acetonitrile (35%) flowing at 4.2 mL/min over 21 min.
Labeled peptide eluted around 8 min, with the acrylodan labeled peptide detected by UV
absorbance at 360 nm. Collected fractions containing labeled peptides were dried under vacuum
at room temperature and resuspended in 1:1 acetonitrile:H2O, and labeling was confirmed by
MALDI-TOF mass spectrometry (Bruker Autoflex III, SUNY-ESF) using a matrix of saturated
sinapinic acid in 0.1% TFA and 50 mM ammonium phosphate. The concentration of
acrylodanylated peptide was determined by absorbance of acrylodan at 360 nm (e = 13,300 M-1
cm-1), and peptide aliquots were stored at -80 °C.
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hGOAT activity assays and analysis
In each assay, microsomal fraction containing approximately 50 µg membrane protein (as
determined by Bradford assay) was incubated with inhibitor at the indicated concentration or
vehicle (DMSO or H2O) for 30 min at room temperature in 50 mM HEPES (pH 7.0) before reaction
initiation with 500 µM octanoyl CoA and 1.5 µM GSSFLCAcDan. Assays were incubated at room
temperature for the times indicated and stopped by addition of equal volume 20% acetic acid in
isopropanol. Reaction solutions were clarified by protein precipitation with 16.7 µL of 20%
trichloroacetic acid followed by centrifugation (1,000 x g, 1 min), with the resulting supernatant
collected for analysis.
Assay samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase column
(Zorbax Eclipse, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05% TFA to 63%
acetonitrile in 0.05% TFA over 14 min, followed by 100% acetonitrile for 10 min. Fluorescent
peptides were detected by fluorescence (lex = 360 nm, lem = 485 nm), with the unacylated peptide
eluting with a retention time of ~6 min and the octanoylated peptide product eluting with a
retention time of ~12 min. Chromatogram analysis and peak integration was performed using
Chemstation for LC (Agilent Technologies).
For octanoyl CoA titration experiments, reactions were performed and analyzed as
described above with the following modifications. Microsomal fraction containing hGOAT was
incubated with 1 µM MAFP in reaction buffer for 30 minutes before initiating the reactions with
indicated concentrations of octanoyl CoA and 1.5 µM GSSFLCAcDan. Reactions were incubated
for 2 hours at room temperature before stopping. To determine Km of octanoyl CoA in the presence
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of MAFP, the plot of integrated product fluorescence versus [octanoyl CoA] was fit to equation 1
using Kaleidagraph (Synergy Software, Reading, PA, USA):
(1)  Integrated product fluorescence = m1 x

[octanoyl CoA]
Km +[octanoyl CoA]

MAFP protection of octanoylated GSSFLCAcDan in microsomal fraction
Octanoyl-GSSFLCAcDan was prepared using the standard hGOAT activity assay described
above, in preparative scale (10 x 1 mL reactions) in the presence of 5 µM MAFP. The product was
purified by reverse phase HPLC (Zorbax Eclipse XDB column, 9.4 x 250 mm) using an isocratic
mobile phase of water containing 0.05% trifluoroacetic acid (TFA) (65%) and acetonitrile (35%)
flowing at 4.2 mL/min over 21 min). The peptide substrate was monitored by absorbance of
acrylodan at 360 nm, collected, and used as the substrate in protection assays.
For microsomal fraction esterase activity assays, approximately 50 µg microsomal protein
from Sf9 cells transfected with hGOAT were incubated with either 5 µM MAFP or DMSO vehicle
in 50 mM HEPES (pH 7.0) for 30 min at room temperature followed by addition of 1.5 µM
octanoyl-GSSFLCAcDan. Reactions were incubated for the indicated times, and were stopped with
the addition of equal volume 20% acetic acid in isopropanol. Reaction solutions were clarified by
protein precipitation with 16.7 µL of 20% trichloroacetic acid followed by centrifugation (1,000 x
g, 1 min), with the resulting supernatant collected for analysis by reverse phase HPLC as described
for hGOAT activity assays.

MAFP protection of exogenously added ghrelin in HEK293FT cell lysate
HEK293FT cells were cultured in DMEM medium (Corning) supplemented with 10%
inactivated fetal bovine serum, 1% penicillin/streptomycin, and 0.01% octanoic acid. Cells were
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routinely passaged 2-3 times per week. Cells were lysed at 3 x 105 cells/100 µL in lysis buffer (50
mM Tris HCl [pH 7.4], 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% sodium dodecyl sulfate,
and Complete Protease Inhibitor Tab; Roche) with or without 5 µM MAFP as appropriate by
vortexing for 3 seconds and freezing at -80 °C for a minimum of 16 hr. Immediately before use,
lysates were thawed on ice, centrifuged at 20,000 x g for 20 min at 4 °C, and the supernatant was
transferred to another 1.5 mL siliconized tube. Lysates were treated with 400 pg/mL human acyl
ghrelin as appropriate and incubated on ice for 120 min before loading onto a human active ghrelin
ELISA plate (EMD Millipore Corp). All samples were assayed in triplicate, with one standard
deviation reported as error bars.

Research animals (Carleton University)
Male Wistar rats were bred and maintained in the Department of Neuroscience at Carleton
University. Rats weighing between 350 and 400 g were used in this study. Before killing, all rats
were housed in pairs in ventilated cages under standard laboratory conditions with a 12-hour light,
12-hour dark cycle with lights on at 7 AM. Animals had free access to standard rat chow (Purina)
and tap water and were kept at constant humidity and temperature ranging from 21 °C to 23 °C.
To obtain blood samples, animals were killed by CO2 inhalation followed by rapid decapitation.
All experimental manipulations were approved by the Carleton University Animal Care
Committee and adhered to the standards of the Canadian Council for Animal Care.
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MAFP protection of exogenously added ghrelin in rat blood plasma (Experiment performed by
Trevor Rodrigues, Carleton University)
Male Wistar rats (n = 4) were used in this study. After killing, the blood sample from each
animal was centrifuged, with plasma divided into 4 tubes and left untreated overnight at 4 °C. The
next morning, the plasma samples from each animal were treated with the following additives: 1)
vehicle alone; 2) vehicle and ghrelin (final concentration 400 pg/mL); 3) MAFP (final
concentration, 5 µM); and 4) ghrelin (final concentration 500 pg/mL) followed by MAFP (final
concentration, 5 µM). Ghrelin stability in assay buffer was also measured in the presence and
absence of MAFP (final concentration, 5 µM); assay buffer with MAFP alone does not yield a
detectable signal. After incubation on ice for 120 minutes, samples were assayed for acyl ghrelin
concentrations using a commercially available acyl ghrelin ELISA (Millipore). All samples were
assayed in duplicate. Variability between duplicates was less than 13%.

Inhibitor protection of endogenous ghrelin in rat blood samples (Experiment performed by Trevor
Rodrigues, Carleton University)
Male Wistar rats (n = 10) were used in this study. Trunk blood from each rat was collected
into 4 different borosilicate tubes containing EDTA. The first sample was treated with 1 N HCl
(10 µL/mL of blood). The second sample was treated with AEBSF (10 µL/mL of blood from a
400 mM stock solution to yield a final concentration of 4 mM [0.9 mg/mL]); the third sample was
treated with MAFP [10 µL/mL of blood from a 500 µM stock solution to yield a final concentration
of 5 µM (1.85 µg/mL)]. The last sample (control) was not treated. Samples were treated with
described ghrelin deacylation inhibition conditions immediately upon blood collection. The
samples from 5 rats were centrifuged for 5 min at 3,000 rpm and incubated on ice for 2 hr before
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being frozen and stored overnight at -20 °C. The samples from additional 5 rats were centrifuged
after treatment and stored immediately at -20 °C. The next morning, samples were thawed and
processed for acyl ghrelin quantification using a commercially available acyl ghrelin ELISA
(Millipore). All samples were assayed in duplicate. Variability between duplicates was less than
10%.
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Chapter 3: Identification and development of small molecule hGOAT inhibitors
Portions of this chapter have been previously published and reprinted with permission from
reference 1: McGovern-Gooch, K. R., Mahajani, N. S., Garagozzo, A., Schramm, A. J., Hannah,
L. G., Sieburg, M. A., Chisholm, J. D., and Hougland, J. L. (2017), Synthetic triterpenoid
inhibition of human ghrelin O-acyltransferase: The involvement of a functionally required cysteine
provides mechanistic insight into ghrelin acylation. Biochemistry, 56:919-931. Copyright 2017,
American Chemical Society. N. Mahajani synthesized compounds 9-14, 16 and 17. A. Garagozzo,
A. J. Schramm, and L. G. Hannah contributed to library screening. M. A. Sieburg performed cellbased inhibition and cytotoxicity assays.
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3.1 Introduction
Ghrelin’s role in diseases such as diabetes, obesity, and Prader-Willi Syndrome highlights
the need to explore treatment avenues to modulate this pathway. There are several potential targets
within the ghrelin signaling pathway: antagonists of GHSR1a prevent ghrelin-induced growth
hormone secretion; anti-ghrelin antibodies and Spiegelmers bind and sequester ghrelin in
circulation; and inhibition of GOAT prevents the acylation of ghrelin, preventing its ability to bind
and activate GHSR1a. In addition, mimics of unacylated ghrelin have been shown to have
biological effects, though their target remains unknown.
Both antagonists and agonists of GHSR1a have been reported as potential therapeutics for
conditions related to growth hormone signaling, with varying degrees of success in clinical and
preclinical trials.2-4 Agonists, which bind to GHSR1a and stimulate the release of growth hormone,
have been developed for conditions such as cachexia and anorexia,5-7 age-related declines in
muscle mass,8,

9

and gastroparesis related to various conditions.10,

11

Antagonists or inverse

agonists of GHSR1a prevent its release of growth hormone, and have potential to treat conditions
such as obesity,12-15 diabetes,13, 14 and addictive behaviors.16-20
Antagonism of ghrelin signaling has also been achieved through a vaccination approach.
Rats producing anti-ghrelin antibodies exhibited decreased weight gain as a result of selective
binding of acylated ghrelin in plasma.21 RNA-based Spiegelmers are also able bind to circulating
acyl ghrelin, preventing growth hormone release in rats,22 inhibiting ghrelin-induced food foraging
and hoarding behavior in Siberian hamsters,23 and promoting weight loss and reducing ghrelininduced food intake in diet-induced obese mice.24 Administration of an anti-ghrelin Spiegelmer to
neonatal mice was used to show that altered ghrelin signaling in the early stages of development
leads to widespread disruption of the neural network in the arcuate nucleus of the hypothalamus,
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providing a possible explanation for the lack of phenotypic changes in ghrelin knockout models.25
Therapeutic applications of anti-ghrelin vaccines or Spiegelmers beyond these studies remain
unexplored.
Inspired by the antagonistic effects of unacylated ghrelin on ghrelin-induced
hyperglycemia and insulin resistance, several research groups have explored unacylated ghrelin
analogs as therapeutics for diabetes. AZP531, a cyclic peptide consisting of residues 6–13 of
ghrelin, prevented insulin resistance and attenuated adiposity induced by a high-fat diet in mice.26
It exhibited similar effects in overweight humans, improving insulin sensitivity and increasing
weight loss without affecting food intake.27 Another unacylated ghrelin analog featuring the first
ten residues of ghrelin with an S3A mutation followed by a Tat sequence for cell permeability,
CF801, was shown to inhibit acyl ghrelin secretion from SG-1 (stomach) cells.28 Mice treated with
CF801 gained less weight, while consuming the same number of calories, when fed a high-fat diet
compared to vehicle-treated mice.28
Lastly, inhibition of GOAT is a potential avenue for modulating ghrelin signaling in vivo.
Acylation of serine 3 is absolutely required for ghrelin to bind and activate GHSR1a,29 and
bioinformatics analysis reveals that ghrelin is GOAT’s only substrate.30 Thus, inhibiting GOAT to
reduce acyl ghrelin levels would be predicted to have limited off-target effects. The few GOAT
inhibitors reported in the scientific literature as of the beginning of this project in 2012 are limited
in their therapeutic potential. Many are peptide-based product or substrate mimetics,31, 32 which
may be unable to cross the cell membrane and may even bind to and activate GHSR1a.33 GO-CoATat, a bisubstrate analog consisting of ghrelin’s N-terminal sequence stably linked to an octanoyl
CoA group and a Tat peptide sequence to enable cell permeability, is currently the only inhibitor
reported to be effective in cell and animal studies.34 The ability of GO-CoA-Tat to lower acyl
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ghrelin in vivo and decrease food intake, weight gain, and insulin resistance34-36 establishes
inhibition of GOAT as a viable therapeutic route to modulating ghrelin signaling.
Small molecule inhibitors of GOAT are especially attractive, as they are more likely than
large peptidomimetics like GO-CoA-Tat to be orally available.37 The only small molecule GOAT
inhibitors reported in the scientific literature have only demonstrated efficacy in a microsomal
assay.38 The discovery of new small molecule GOAT inhibitors will advance the field toward the
development of orally available therapeutics targeting ghrelin signaling, as well as providing a tool
for studying the effects of GOAT inhibition in vivo.
As the active site structure of GOAT is not known, we sought to identify new small
molecule inhibitors of hGOAT through screening a library of small molecules. After discovery of
lead compounds, structure-activity analysis of the best candidate molecule revealed this inhibitor
acted by reversibly alkylating a nucleophilic cysteine residue within the enzyme. This was the first
demonstration that hGOAT may contain a functionally essential cysteine. However, the mouse
isoform of GOAT is not susceptible to these or other cysteine-modifying inhibitors, indicating an
unexpected mechanistic distinction between the two closely related enzymes.
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3.2 Results
Screening of Diversity Set IV library reveals lead compounds
To identify novel small molecule inhibitors of hGOAT, we used our HPLC-based
fluorescence assay to screen compounds from the Diversity Set IV small molecule library from
the NIH’s Developmental Therapeutics Program (DTP).39,

40

This library contains 1,596

compounds representing diverse chemical scaffolds from the DTP repository. Compounds were
initially screened at 10 and 100 µM, with compounds exhibiting dose-dependent inhibition and £
50% activity relative to the vehicle control selected for a secondary screen under the same
conditions (Figure 3.1). To date, 478 compounds from the library have been screened, and 14 have
satisfied these criteria.
The most promising candidate molecule from this initial screen was identified as 1-[2cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole

(CDDO-Im),

a

synthetic

oleanate

triterpenoid derived from oleanolic acid.41 A closely structurally related compound, CDDO-Me,
also inhibited hGOAT activity (Figure 3.2). Therefore, we chose to pursue structure-activity
analysis of this scaffold.
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Figure 3.1 Screening format for identification of novel small molecule inhibitors of hGOAT.
(a) Fluorescence-based hGOAT activity assay used for compound screening. (b) Protocol for
the screening assay to identify hGOAT inhibitors. Reprinted with permission from reference
1. © 2017, American Chemical Society.
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Figure 3.2 Multiple CDDO derivatives effectively inhibit hGOAT. (a) Structures and measured
IC50 values for CDDO derivatives with substitutions at the carboxyl group at position 28: R =
imidazole (CDDO-Im), R = methyl ester (CDDO-Me), R = ethylamide (CDDO-EA), R =
trifluoroethylamide (CDDO-TFEA), and R = carboxylic acid (CDDO). (b-e) Inhibition of
hGOAT octanoylation activity by (b) CDDO-Im, (c) CDDO-Me, (d), CDDO-EA, and (e)
CDDO-TFEA. Reactions were performed and analyzed to determine percent activity. Error bars
reflect the standard deviation from a minimum of three independent measurements. Reprinted
with permission from reference 1. © 2017, American Chemical Society.
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Structure-activity analysis of hGOAT inhibition by CDDO family compounds
In addition to CDDO-Im and CDDO-Me, this class of synthetic triterpenoids also contains
CDDO, CDDO-EA, and CDDO-TFEA. (Figure 3.2) These orally available compounds have
demonstrated antiangiogenic and antitumor activities by modulating the Nrf2- and NF-kBdependent cellular signaling pathways.41-44 We received these three additional compounds as a gift
from the Gribble lab at Dartmouth College and tested each for activity against hGOAT. All but
the parent molecule, CDDO, inhibited ghrelin acylation (Figure 3.2). The lack of activity by
CDDO, which bears a carboxylate group, may reflect the inability of hGOAT to accept negative
charge within its active site.30, 31
To further explore the structural parameters determining the CDDO-based inhibitors’
activity against hGOAT, we evaluated the activity of several structural analogs of these
compounds (Figure 3.3). Natural triterpenoids ursolic acid (6), oleanolic acid (7), and taraxerol (8)
do not inhibit hGOAT activity at concentrations £ 100 µM. All three of these compounds share
the triterpenoid scaffold of the CDDO class of inhibitors, suggesting that this scaffold is not
sufficient for inhibitor potency. Importantly, taraxerol (8) does not feature a carboxylate group, as
ursolic acid (6) and oleanolic acid (7) do, which further supports that the triterpenoid scaffold is
not sufficient for activity.
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Figure 3.3 Structure activity analysis reveals multiple pharmacophores contribute to inhibition
of hGOAT by synthetic triterpenoids. Compounds organized by overall hydrocarbon skeleton
family (triterpenoid, steroid, or cyclohexane parent structure) and colored to reflect potential
pharmacophores (a,b-unsaturated ketone, green; steroid scaffold, purple; CDDO derivative
functional groups in rings C-E, orange). Measured IC50 values are provided for each compound,
with lower limits established based on compound solubility and lack of inhibition observed at
the highest experimentally accessible concentration. Reprinted with permission from reference
1. © 2017, American Chemical Society.
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The a-cyanoenone moiety on the A ring of the CDDO molecules has been shown to modify
nucleophilic cysteine residues within receptors to exert their antitumor activities.45 Therefore, we
hypothesized this functional group may be required for hGOAT inhibition. To test this hypothesis,
a series of minimally functionalized steroid derivatives featuring an a,b-unsaturated ketone in the
position analogous to that in the CDDO derivatives was synthesized by Nivedita Mahajani of the
Chisholm lab. Compound 9, which features the strongly electron-withdrawing a-cyano group
present in the CDDO derivatives, inhibits hGOAT with an IC50 of 8 ± 2 µM, nearly identical to
that of CDDO-Me and CDDO-EA (Figures 3.3 and 3.4a). The similar activity of compound 9 and
CDDO-Me and -EA indicates that the complete triterpenoid scaffold and other functional groups
within the CDDO molecule are not necessary for inhibitor potency. Compounds 10 and 11 bear a
less strongly electron-withdrawing bromine and a non-electron-withdrawing hydrogen,
respectively, at this position. Both inhibit hGOAT, though less strongly than compound 9, with
inhibitor potency scaling with level of electrophilic activation of the enone to nucleophilic addition
(Figures 3.3 and 3.4b-c). Removal of the unsaturation in either the isolated ketone (compound 12)
or the a-bromo ketone (compound 13) result in complete loss of inhibitory activity at
concentrations £ 400 µM. Moving the unsaturation to the other side of the ketone (compound 14)
similarly abrogates activity, indicating that hGOAT inhibition exhibits regioselectivity toward the
enone. The lack of inhibition by estrone (15) demonstrates that the planar conformation of the A
ring is not sufficient for inhibition (Figure 3.3).
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Figure 3.4 Inhibition of hGOAT by steroid derivatives. (a) Inhibition of hGOAT octanoylation
activity by compound 9. (b) Inhibition of hGOAT octanoylation activity by compound 10. (c)
Inhibition of hGOAT octanoylation activity by compound 11. Reactions were performed and
analyzed to determine percent activity as described in the Materials and methods section. Error
bars reflect the standard deviation from a minimum of three independent measurements.
Reprinted with permission from reference 1. © 2017, American Chemical Society.
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We next determined the contribution of the steroid scaffold to inhibitor potency of
compounds 9-11 by measuring inhibition of cyclohexenone derivatives 16-18, which feature the
same series of activation (Figures 3.3 and 3.5). Both a-cyanocyclohexenone (16) and abromocyclohexenone (17) inhibit hGOAT less potently than their steroid analogs, and the
nonactivated cyclohexenone (18) does not inhibit hGOAT at concentrations £ 1 mM, indicating
that the steroid scaffold contributes significantly to inhibitor potency. This contribution likely
arises from a combination of enhanced binding of the inhibitor to the enzyme and decreased
reactivity of the inhibitor with other proteins within the microsomal fraction.

CDDO derivatives inhibit hGOAT through a reversible, covalent modification of a functionally
essential cysteine residue
The necessity for an activated enone within the CDDO-based hGOAT inhibitors suggests
a mechanism involving the alkylation of a nucleophilic cysteine residue involved in hGOAT
catalysis. We determined that hGOAT is susceptible to inactivation by N-ethylmaleimide (NEM),
a common thiol-modifying reagent (Figure 3.6), supporting the involvement of a cysteine residue
in ghrelin acylation.

91

Figure 3.5 Inhibition of hGOAT activity by cyclohexenone derivatives. (a) Inhibition of
hGOAT octanoylation activity by compound 16. (b) Inhibition of hGOAT octanoylation
activity by compound 17. Reactions were performed and analyzed to determine percent activity
as described in the Materials and methods section. Error bars reflect the standard deviation from
a minimum of three independent measurements. Reprinted with permission from reference 1.
© 2017, American Chemical Society.
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Figure 3.6 hGOAT inhibition profile supports the involvement of a catalytically essential
cysteine residue. (a) hGOAT octanoylation activity is inhibited by N-ethylmaleimide (NEM,
shown in inset). Error bars reflect the standard deviation of three independent determinations.
(b) Topological model of hGOAT, with cysteine residues colored yellow and conserved
functionally essential residues N307 and H338 colored red. This model was constructed by
comparison to the experimentally developed topology model for mouse GOAT using the Protter
online server.46, 47 Reprinted with permission from reference 1. © 2017, American Chemical
Society.
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CDDO has been shown to react with nucleophilic thiols selectively at the a-cyanoenone of
ring A through a covalent reversible Michael addition, with the retro-Michael addition facilitated
by the increased acidity of the a proton geminal to the cyano group.45, 48 Covalent modification by
these inhibitors is supported by the time-dependent inhibition of hGOAT (Figure 3.7a). In this
mechanism, a noncovalent enzyme-inhibitor complex is rapidly formed, followed by a slower
covalent alkylation of the cysteine thiol by the a-cyanoenone. At short preincubation times, these
inhibitors are less effective as evidenced by a higher IC50 value. The reversibility of inhibition by
CDDO-EA and compound 9 was demonstrated through a pulse-dilution experiment, in which
hGOAT was preincubated with the inhibitor at 3 times its IC50 concentration followed by a 10fold dilution into either reaction buffer or buffer containing the same inhibitor concentration
(Figure 3.7b). NEM exhibits irreversible hGOAT inhibition, with no increase in hGOAT activity
following dilution of the inhibitor, consistent with irreversible cysteine alkylation. [Dap3]octanoylghrelin (1-5)-NH2, a non-covalent product mimetic inhibitor,31 exhibits expected reversible
inhibition with the observed hGOAT activity increasing after inhibitor dilution. Both CDDO-EA
and compound 9 exhibited reversible inhibition, supporting that these compounds inhibit hGOAT
through the covalent Michael addition of nucleophilic cysteine residue.
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Figure 3.7 hGOAT inhibition profile supports a covalent reversible mechanism of inhibition.
(a) Time dependence of hGOAT inhibition by CDDO-EA. hGOAT activity was measured as a
function of preincubation time in the presence of 30 µM CDDO-EA. The inset shows IC50
values for CDDO-EA inhibition of hGOAT activity as a function of inhibitor preincubation
time. (b) Inhibitor dilution assays reveal irreversible hGOAT inhibition by NEM and reversible
inhibition by CDDO-EA and a-cyanoenone steroid 9. (c) Inhibitor dilution assays reveal
reversible hGOAT inhibition by steroids 10 and 11. Dap-C8 denotes [Dap3]octanoyl-ghrelin(15)-NH2 product-mimetic hGOAT inhibitor used as a control for reversible inhibition. Error bars
reflect the standard deviation from a minimum of three determinations. (a) and (b) reprinted
with permission from reference 1. © 2017, American Chemical Society.
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Steroid-based inhibitors 10 and 11 also exhibited reversible inhibition, with hGOAT
activity increasing after inhibitor dilution (Figure 3.7c). Given the lack of an electron-withdrawing
group in compound 11 and the decreased acidities of the a proton in the resulting conjugate with
hGOAT relative to compound 9, inhibition by compound 11 was expected to be irreversible. While
compound 10 features a moderately electron-withdrawing bromine at the a position, its reversible
behavior was also somewhat surprising.

CDDO-Me and CDDO-EA decrease acyl ghrelin concentrations in HEK293FT cells
There are currently no small molecule GOAT inhibitors reported to be effective in cell or
animal models, with only GO-CoA-Tat demonstrating the ability to lower acyl ghrelin levels in
cell and animal models.34 CDDO derivatives have been extensively studied in multiple biological
systems, and their oral availability is well-established.41-43 The most potent CDDO derivatives
against hGOAT in our enzyme activity assay, CDDO-Me and CDDO-EA, were chosen to
determine their ability to inhibit GOAT-catalyzed acylation of ghrelin in a cellular assay.
HEK293FT cells stably transfected to express preproghrelin and the mouse isoform of
GOAT (mGOAT) and were treated with CDDO, CDDO-Me, or CDDO-EA.34 Cellular acyl ghrelin
levels were determined by ELISA. CDDO, which was not active against hGOAT in the enzymatic
assay, did not significantly lower acyl ghrelin levels at concentrations below 1 µM (Figure 3.8a).
Both CDDO-Me and CDDO-EA reduced acyl ghrelin levels with cellular IC50 values of 35 ± 10
nM and 320 ± 150 nM, respectively. These concentrations for effective reduction of acyl ghrelin
are far below the onset of cytotoxicity. Apparent LD50 values for CDDO-Me and CDDO-EA were
both around 10 µM in the HEK293FT cells used (Figure 3.8b).
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Figure 3.8 Acyl ghrelin levels are decreased by treatment with CDDO-EA and CDDO-Me in
a cellular assay. (a) Dose-dependent reduction of acyl ghrelin concentrations in
mGOAT/preproghrelin transfected HEK293FT cells following 24 hours incubation,
normalized to the DMSO vehicle. CDDO, white bars; CDDO-EA, gray bars; and CDDO-Me,
black bars. Error bars reflect the standard deviation from three independent measurements. (b)
Cell viability for mGOAT/preproghrelin transfected HEK293FT cells following 24 hours
incubation, normalized to the DMSO vehicle. CDDO, white bars; CDDO-EA, gray bars; and
CDDO-Me, black bars. Error bars reflect the standard deviation from three independent
measurements.
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Mouse GOAT is not susceptible to cysteine-modifying inhibitors
The effective concentrations of both CDDO-Me and CDDO-EA for lowering acyl ghrelin
levels in the cellular assay were substantially lower than those determined in the hGOAT activity
assay. This discrepancy could arise from increased susceptibility of mGOAT used in the cellular
assays to inhibition by these compounds compared to hGOAT, which was used for all enzyme
activity assays.
Unexpectedly, we found that CDDO-EA inhibits mGOAT less potently than it inhibits
hGOAT, with an IC50 value of 60 ± 8 µM for the mouse isoform (Figure 3.9). To explore the cause
of this loss of potency, we determined whether inhibition of mGOAT exhibits the same
chemoselectivity for the electrophilic enone demonstrated for hGOAT. Both enzymes were treated
with a-cyanoenone 9 or ketone 12. These steroid derivatives differ only in the a-nitrile and a,bunsaturation of ring A (Figure 3.3), so any difference in inhibition activity against GOAT can be
directly attributed to the enzyme’s chemoselectivity for the a-cyanoenone. Compound 9 potently
inhibits hGOAT, while ketone 12 is inactive at concentrations £ 100 µM, indicating the
electrophilic enone is providing an enhancement in potency. In contrast, the presence of the
cyanoenone does not provide an enhancement of potency against mGOAT (Figure 3.10a). In
addition, mGOAT is resistant to inhibition by NEM in contrast to hGOAT (Figure 3.10b).
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Figure 3.9 The mouse isoform of GOAT (mGOAT) is not as strongly inhibited by CDDO-EA
as is hGOAT. Inhibition of hGOAT (black circles) and mGOAT (gray circles) as a function of
CDDO-EA concentration. Error bars reflect the standard deviation of three independent
measurements. Reprinted with permission from reference 1. © 2017, American Chemical
Society.
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Figure 3.10 hGOAT and mGOAT exhibit dramatically different susceptibilities to inhibition
by cysteine-modifying agents. (a) Inhibition by hGOAT (left) and mGOAT (right)
octanoylation activity by a-cyanoenone 9 (black bars) and ketone 12 (gray bars). (b) Inhibition
of hGOAT (black bars) and mGOAT (gray bars) octanoylation activity by N-ethylmaleimide
(NEM). Error bars reflect the standard deviation from a minimum of three independent
measurements. Reprinted with permission from reference 1. © 2017, American Chemical
Society.
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This resistance of mGOAT to inhibition was unexpected, as the two isoforms exhibit a high
level of homology (79% identical and 92% similar) (Figure 3.11). In particular, residues required
for enzyme activity are generally highly conserved, and the high degree of sequence conservation
suggests the enzymes employ the same catalytic mechanism. Alignment of the hGOAT and
mGOAT protein sequences reveals several cysteine residues in the human enzyme that are not
conserved in the mouse isoform (Figure 3.11). This discrepancy in susceptibility to cysteine
modifying compounds between these two closely related isoforms of GOAT suggests that either
mGOAT does not contain a functionally essential cysteine, or that the functionally essential
cysteine is resistant to modification by NEM and the cyanoenone inhibitors used in this work.
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Figure 3.11 Clustal Omega alignment of hGOAT and mGOAT sequences. Cysteine residues
are shown in bold, with cysteines conserved in both isoforms highlighted in gray, and cysteine
residues unique to hGOAT highlighted in yellow. Reprinted with permission from reference 1.
© 2017, American Chemical Society.
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3.3 Discussion and conclusions
Synthetic triterpenoids CDDO-Me and CDDO-EA, as well as their steroid-based
counterpart compound 9, represent a new class of hGOAT inhibitors. These molecules are only
the second reported class of small molecule GOAT inhibitors, and the first reported inhibitors that
do not bear a medium-length lipid chain mimicking the octanoyl group of the acyl donor
substrate.31, 32, 34, 38 Structure activity analysis of these compounds reveal a novel mechanism for
hGOAT inhibition involving the covalent Michael addition of a nucleophilic cysteine residue to
the a-cyanoenone, and inhibitor dilution experiments establish that inhibition by these groups is
reversible. Surprisingly, steroids 10 and 11, which contain a bromine and hydrogen at the a
position, respectively, also displayed behavior consistent with reversible inhibition. The a protons
in the enzyme-inhibitor conjugates resulting from covalent inhibition by these compounds are not
expected to be acidic enough to enable a reversible Michael reaction. One possible explanation for
the observed behavior is that these inhibitors modify a cysteine residue within the active site of
hGOAT, blocking activity, and the proposed general base (such as the conserved and functionally
required H33849-51) catalyzes the reverse Michael reaction. However, in the case of compound 11,
there is a dramatic difference between observed activity under the undiluted and diluted reaction
conditions, with the undiluted reaction – containing 600 µM inhibitor – resulting in no or minimal
enzyme activity, behavior which is not seen with other compounds with lower IC50 values. This
nearly complete loss of activity under these reaction conditions may reflect issues of inhibitor
solubility, rather than true enzyme inhibition. Looking forward, steroid compounds featuring a
thioether adduct at the b position may enable the direct monitoring of the reverse Michael reaction.
Treatment of HEK293FT cells expressing mGOAT and preproghrelin with CDDO-EA and
CDDO-Me resulted in reduced concentrations of acyl ghrelin. However, enzymatic assays
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comparing the mouse and human isoforms of GOAT revealed that mGOAT is less susceptible to
inhibition by these synthetic triterpenoids, and does not exhibit chemoselectivity for inhibition by
cysteine-modifying compounds. Therefore, the reduced concentrations of acyl ghrelin upon
treatment with CDDO derivatives in cell-based assays likely resulted, at least in part, from
mechanisms aside from GOAT inhibition. Total ghrelin (acyl + unacylated) concentrations could
not be determined due to unreliability of the commercial ELISA kit for total ghrelin. CDDO
derivatives have been shown to modulate cytoprotective and apoptotic genes regulated through the
Nrf2 and NF-kB transcription factors,41 and it is possible that treatment with these compounds
reduced expression of ghrelin and/or GOAT, resulting in the observed decreased concentrations
of acyl ghrelin.
Confirmation that synthetic triterpenoids inhibit GOAT in cells will rely on the
development of a cellular assay using hGOAT and a method for reliably determining
concentrations of total ghrelin. However, clinical and preclinical trials of CDDO derivatives have
reported side effects that may be consistent with altered ghrelin signaling, including reduced fat
deposition, improved glucose tolerance, prevention of insulin resistance, and weight loss.52-55
Future studies investigating the effects of these molecules in either animal models or human
patients should incorporate the monitoring of ghrelin levels to establish whether GOAT is a true
target (or off-target) or these drugs in vivo.
Aside from the therapeutic implications of this study, inhibition by synthetic triterpenoids
also provided fundamental information about GOAT. Structure-activity analysis of the steroidbased inhibitors and inhibition by NEM established that hGOAT catalysis may involve a
functionally essential cysteine. There are 16 cysteine residues within hGOAT, with the majority
of them located outside the conserved C-terminal “MBOAT” domain.56 Mutational analyses of
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GOAT, Hhat, and PORCN have revealed functionally essential residues, but none have implicated
cysteine residues as being functionally essential.31, 46, 49, 51, 57-60 The specific role of the modified
cysteine residue(s) is unclear. If the cysteine responsible for hGOAT inhibition by these
compounds is in fact catalytic, it may act by forming an acyl-enzyme intermediate, transferring
the octanoyl group from octanoyl CoA to ghrelin (Figure 3.12). A similar mechanism has been
proposed for protein palmitoylation by DHHC palmitoyl transferases.61,
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The resistance of

mGOAT to inhibition by cysteine-modifying molecules argues that the cysteine responsible for
inhibition of hGOAT is not catalytic. In this case, the cysteine residue within hGOAT may be
located in or near the active site, so that modification by inhibitors of this residue sterically blocks
the active site. Given either possibility, the cysteine residues(s) involved in inhibition by these
inhibitors may serve as a chemical handle to determine the enzyme’s catalytic machinery.
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Figure 3.12 Potential mechanism for hGOAT-catalyzed ghrelin octanoylation employing a
cysteine acyl-enzyme intermediate. Following formation of an octanoyl-enzyme intermediate,
transfer of the octanoyl group to the serine acylation site near the N-terminus of ghrelin can be
catalyzed through the involvement of a general base such as the conserved and functionally
essential H338 residue. Reprinted with permission from reference 1. © 2017, American
Chemical Society.
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3.4. Materials and methods
General
Data plotting and curve fitting were performed with Kaleidagraph (Synergy Software).
Methoxy arachidonyl fluorophosphonate (MAFP) was purchased from Cayman Chemical (Ann
Arbor, MI) as a stock in methyl acetate and diluted in DMSO prior to use. Octanoyl coenzyme A
(octanoyl CoA) was purchased from Advent Bio (Downers Grove, IL) solubilized to 5 mM in 10
mM Tris-HCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored at -80 °C.
Acrylodan (Anaspec) was solubilized in acetonitrile, with the stock concentration determined by
absorbance at 393 nm upon dilution into methanol (e = 18,483 M-1 cm-1 per manufacturer’s data
sheet). N-ethylmaleimide (NEM) was purchased from Tokyo Chemical Industry (Portland, OR),
and dissolved in ethanol prior to use. CDDO-Me, CDDO-EA, CDDO-Im, CDDO-TFEA, and
CDDO were gifts from G. Gribble and M. Sporn (Dartmouth College, Hanover, NH). Compounds
6-8 and 15 were obtained from the Developmental Therapeutics Program (DTP) of the National
Institutes of Health (NIH). Compounds 9-14, 16, and 17 were synthesized by Nivedita Mahajani
as described below. Estrone (15) was purchased from Cayman Chemical. Cyclohexenone (18) was
purchased from Alfa Aesar (Ward Hill, MA). The GSSFLCNH2 peptide for fluorescent labeling
with acrylodan was synthesized by Sigma-Genosys in the Pep-screen format, and solubilized in
1:1 acetonitrile: H2O and stored at -80 °C. Peptide concentration was determined by absorbance at
412 nm following reaction of the cysteine thiol with 5,5’-dithiobis(2-nitrobenzoic acid) using e =
14,150 M-1 cm-1.63
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Expression and enrichment of hGOAT and mGOAT
Genes encoding hGOAT or mGOAT with a C-terminal triple tag (FLAG, HA, His6) were
cloned into the pFastBacDual vector (Invitrogen) using EcoRI and XbaI restriction sites, with the
resulting vector used to produce the baculovirus expression system protocol (Invitrogen). Sf9
insect cells (5.0 x 108 cells in a 500 mL total culture volume) were infected with hGOAT
baculovirus at a multiplicity of infection of 10 followed by protein expression for 40 hr at 28 °C
with shaking at 150 rpm. Cells were harvested by centrifugation (500 x g, 5 min), and freezing the
pellet at -80 °C. The cell pellets were thawed on ice, resuspended in 25 mL lysis buffer [150 mM
NaCl, 50 mM Tris-HCl (pH 7.0), 1 mM sodium ethylenediamine tetraacetate (NaEDTA), 1 mM
dithiothreitol (DTT), complete protease inhibitor (Roche), 10 µg/mL pepstatin A, and 100 µM
bis(4-nitrophenyl)phosphate]. The resuspended cells were lysed with a Dounce homogenizer on
ice, followed by removal of cell debris by centrifugation (3,000 x g, 4 °C, 10 min). The microsomal
fraction was then isolated by ultracentrifugation of the supernatant (100,000 x g, 4 °C, 1 hr). The
isolated microsomal fraction pellet was resuspended in 50 mM HEPES (pH 7.0) and stored in lowadhesion microcentrifuge tubes at -80 °C until use.

Peptide substrate fluorescent labeling
GSSFLCNH2 (300 µM) and acrylodan (500 µM) were dissolved in 500 µL 1:1 50 mM
HEPES (pH 7.8):acetonitrile, followed by incubation at room temperature in the dark for 18 hr
with shaking. Acrylodan-labeled peptide was purified by reverse phase HPLC (Zorbax Eclipse
XDB column, 9.4 x 250 mm) using an isocratic mobile phase of water containing 0.05%
trifluoroacetic acid (TFA) (65%) and acetonitrile (35%) flowing at 4.2 mL/min over 21 min).
Labeled peptide eluted around 8 min, monitoring UV absorbance at 360 nm. Collected fractions
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containing labeled peptides were dried under vacuum at room temperature and resuspended in 1:1
acetonitrile:H2O, and labeling was confirmed by MALDI-TOF mass spectrometry (Bruker
Autoflex III, SUNY-ESF) using a matrix of saturated sinapinic acid in 0.1% TFA and 50 mM
ammonium phosphate. Concentration of acrylodanylated peptide was determined by absorbance
of acrylodan at 360 nm (e = 13,300 M-1 cm-1), and was stored at -80 °C.

hGOAT and mGOAT activity assays and analysis
Microsomal fraction from Sf9 cells expressing hGOAT or mGOAT were thawed on ice
and passed through an 18-gauge needle 10 times to homogenize the fraction. Assays were
performed with ~100 µg of microsomal protein, as determined by a Bradford assay. The
microsomal fraction was preincubated with 1 µM MAFP and inhibitor or vehicle as indicated in
50 mM HEPES (pH 7.0) for 30 min at room temperature. Reactions were initiated with the addition
of 500 µM octanoyl CoA and 1.5 µM fluorescently labeled ghrelin mimetic GSSFLCAcDan in a
total volume of 50 µL, and were incubated for 3 hr, then stopped with the addition of 50 µL of
20% acetic acid in isopropanol, and solutions were clarified by protein precipitation with 16.7 µL
of 20% trichloroacetic acid (TCA) followed by centrifugation (1,000 x g, ~1 min). The supernatant
was analyzed by reverse phase HPLC. Data reported are the average of three independent
determinations, with error bars representing one standard deviation.
Assay samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase column
(Zorbax Eclipse, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05% TFA to 63%
acetonitrile in 0.05% TFA over 14 min, followed by 100% acetonitrile for 10 min. Fluorescent
peptides were detected by fluorescence (lex = 360 nm, lem = 485 nm), with the unacylated peptide
eluting with a retention time of ~6 min and the octanoylated peptide product eluting with a
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retention time of ~12 min. Chromatogram analysis and peak integration was performed using
Chemstation for LC (Agilent Technologies).

Library screening
For screening of the Diversity Set IV library of small molecules, hGOAT octanoylation
reactions were performed as described above with the addition of library compounds at
concentrations of 10 and 100 µM. Compounds that met the criteria for inhibition (dose-dependent
decrease in activity, <50% activity at 100 µM) were confirmed with a secondary screen using the
same protocol.

Determination of IC50 values in in vitro hGOAT and mGOAT activity assays
Reactions were performed and analyzed as described in the presence of either inhibitor or
vehicle as appropriate. The percent activity at each inhibitor concentration was calculated from
HPLC integration data using equations 1 and 2:
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To determine the IC50 value, the plot of % activity versus [inhibitor] was fit to equation 3,
with % activity0 denoting hGOAT activity in the presence of vehicle alone:
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Determination of inhibitor time dependence with hGOAT
Assays were performed and analyzed as described above with the following modifications.
The microsomal fraction was preincubated with 1 µM MAFP in 50 mM HEPES (pH 7.0) for 30
min at room temperature, and incubated with inhibitor or vehicle as appropriate for varying times
(5, 10, 30, and 60 min) prior to initiation of the reaction. Reactions were incubated at 10 min at
room temperature in the dark, followed by addition of stop solution and reaction workup and
analysis as described above.

Inhibitor reversibility assay
The undiluted homogenized microsomal fraction containing hGOAT (protein
concentration of ~7 µg/µL) was incubated with 10 µM MAFP and 3 x (IC50) or equal volume
vehicle for 30 min at room temperature. The microsomal fraction/inhibitor solution was diluted
10-fold into a reaction mixture containing 500 µM octanoyl CoA, 1.5 µM GSSFLCAcDan, 50 mM
HEPES (pH 7.0.), and either vehicle or inhibitor [final concentration of 3 x (IC50)] in a total
reaction volume of 50 µL. Reaction mixtures were incubated at 3 hours at room temperature in the
dark and analyzed as described above.

Cell line generation and culture
Stably transfected GOAT/preproghrelin HEK 293FT cells were generated using the
phPPG-mGOAT plasmid (a gift from Dr. Jef Boeke’s laboratory, NYU Langone Medical Center)
containing human preproghrelin (hPPG) and mouse ghrelin O-acyltransferase (mGOAT)
connected by an intervening encephalomyocarditis virus internal ribosome entry site (ECMVIRES) under puromycin selection as previously described.34 Cells were transfected using
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Lipofectamine 2000 (Invitrogen) at a 2 µL to 1 µg DNA ratio in 10 cm tissue culture-treated dishes
according to manufacturer’s protocol. The 293FT-hPPG-mGOAT cells were cultured in DMEM
medium

(Corning)

supplemented

with

10%

inactivated

fetal

bovine

serum,

1%

penicillin/streptomycin, 1 µg/mL puromycin, and 0.01% octanoic acid and routinely passaged 23 times per week. A clonal line was chosen through serial dilution into a 96-well plate.

Inhibitor treatment, cell lysate preparation, and acyl ghrelin concentration measurement by ELISA
Cell density and number were optimized for detection of acyl ghrelin via ELISA (EMD
Millipore Corp). HEK293FT-hPPG-mGOAT clonal cells were plated in 24-plates at 2 x 105
cells/well. Cells were incubated overnight at 37 °C, 5% CO2 and treated the next morning with
inhibitors or vehicle (DMSO) in triplicate. Cells were treated for 24 hr and harvested after medium
aspiration using 40 µL/well trypsin-EDTA (0.25%, Corning) containing 5 µM methoxy
arachidonyl fluorophosphonate (MAFP). Cells were transferred to 1.5 mL siliconized tubes with
200 µL PBS containing 5 µM MAFP and centrifuged at 800 x g for 5 min. The pellet was
resuspended in 100 µL lysis buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1%
NP-40, 0.1% SDS, Complete Protease Inhibitor Tab (Roche), 5 µM MAFP), vortexed for 3
seconds on high and frozen at -80 °C for a minimum of 16 hr. Immediately before use, lysates
were thawed on ice, centrifuged at 20,000 x g for 20 min at 4 °C, and the supernatant was
transferred to another 1.5 mL siliconized tube. Lysate was diluted 1:2 with lysis buffer before
loading onto Human Active Ghrelin ELISA plates (EMD Millipore Corp).

Samples were

incubated with the capture and detection antibodies for 3.5 hr shaking at room temperature, with
all other steps performed according to manufacturer’s protocol.
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Determination of inhibitor cytotoxicity by AlamarBlue assay
HEK293FT-hPPG-mGOAT cells were plated into 96-well plates at 2 x 104 cells/well the
evening before inhibitor addition. Cells were treated with inhibitor and 10% (v/v) AlamarBlue
(Invitrogen) for 24 hr, followed by determination of cell viability according to the manufacturer’s
protocol using a Synergy H1 Hybrid plate reader (BioTek).

General information for synthetic methods (Syntheses performed by Nivedita Mahajani, Syracuse
University)
All anhydrous reactions were run under a positive pressure of argon or nitrogen. All
syringes, needles, and reaction flasks required for anhydrous reactions were dried in an oven and
cooled under an N2 atmosphere or in a desiccator. DCM and THF were dried by passage through
an alumina column by the method of Grubbs.64 Triethylamine was distilled from CaH2. All other
reagents and solvents were purchased from commercial sources and used without further
purification
Analytical thin layer chromatography (TLC) was performed on precoated glass backed
plates (silica gel 60 F254; 0.25 mm thickness). The TLC plates were visualized by UV illumination
and by staining. Solvents for chromatography are listed as volume:volume ratios. Flash column
chromatography was carried out on silica gel (40-63 µm). Melting points were recorded using an
electrothermal melting point apparatus and are uncorrected. Elemental analyses were performed
on an elemental analyzer with a thermal conductivity detector and 2 meter GC column maintained
at 50 °C.
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Ketone 12,65 α-bromoketone 13,66, 67 enone 14,68 2-cyano-2-cyclohexanone 16,69 and 2bromo-2-cyclohexanone 1770 were prepared and purified as previously described. Estrone 15 and
2-cyclohexen-1-one 18 were purchased from commercial sources.

Identity (performed by Nivedita Mahajani, Syracuse University)
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were
recorded at 300 or 400 MHz and 75 or 100 MHz respectively. The chemical shifts are given in
parts per million (ppm) on the delta (δ) scale. Coupling constants are reported in hertz (Hz). The
spectra were recorded in solutions of deuterated chloroform (CDCl3), with residual chloroform (δ
7.26 ppm for 1H NMR, δ 77.23 ppm for 13C NMR) or tetramethylsilane (δ 0.00 for 1H NMR, δ
0.00 for 13C NMR) as the internal reference. Data are reported as follows: (s = singlet; d = doublet;
t = triplet; q = quartet; p = pentet; sep = septet; dd = doublet of doublets; dt = doublet of triplets;
td = triplet of doublets; tt = triplet of triplets; qd = quartet of doublets; ddd = doublet of doublet of
doublets; br s = broad singlet). 1H and 13C NMR spectra for compounds 9-11 are provided in Figure
13. Infrared (IR) spectra were obtained as thin films on NaCl plates by dissolving the compound
in DCM followed by evaporation or as KBr pellets.
Synthesis of (5S,8S,9S,10S,13S,14S)-10,13-dimethyl-3-oxo-4,5,6,7,8,9,10,11,12,13,14,15,16,17tetradecahydro-3H-cyclopenta[a]phenanthrene-2-carbonitrile

(compound

9).

(Synthesis

performed by Nivedita Mahajani, Syracuse University)
To a stirred solution of bromo enone 10 (0.210 g, 0.597 mmol) in anhydrous DMF (5.9
mL) was added copper (I) cyanide (0.059 g, 0.657 mmol) and potassium iodide (0.020 g, 0.2
mmol). The resulting reaction mixture was heated to 120 °C for 36 hr. After the completion of
reaction, it was cooled to room temperature, quenched with water (5 mL), and diluted with ethyl
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acetate (15 mL). The organic phase was washed with saturated NaHCO3 (2 x 5 mL) and brine (5
mL), dried over sodium sulfate, filtered and concentrated. Silica gel column chromatography on
the residue (8% ethyl acetate/92% hexanes) provided 0.070 g (40%) of cyano enone 9 as white
solid. This procedure was adapted from the work of Gribble.71
mp = 171-173 °C; TLC Rf = 0.61 (20% ethyl acetate/80% hexanes); IR (thin film from
1
DCM) 3411, 2230, 1693, 1447, 1216 cm–1; [a]=>
< = +1.46 (c = 0.05, DCM); H NMR (400 MHz,

CDCl3) δ 7.87 (s, 1H), 2.47-2.34 (m, 2H), 2.00-1.92 (m, 1H), 1.84-1.54 (m, 7H), 1.50-1.38 (m,
5H), 1.22- 1.12 (m, 3H), 1.08 (s, 3H), 1.05-0.94 (m, 2H), 0.73 (s, 3H);

13

C NMR (100 MHz,

CDCl3) δ 192.4, 169.8, 115.8, 114.5, 54.3, 49.4, 43.2, 40.9, 40.1, 38.4, 35.9, 35.8, 31.3, 27.3, 25.3,
22.6, 21.2, 20.5, 17.6, 12.6. HRMS (ESI+) calculated for C20H27NONa: 320.1984, Found:
320.1981. Anal. calculated for C20H27NO: C, 80.76; H, 9.15; N, 4.71. Found: C, 80.37; H, 9.13;
N, 4.48.

(5S,8S,9S,10S,13S,14S)-10,13-dimethyl-3-oxo-4,5,6,7,8,9,10,11,12,13,14,15,16,17tetradecahydro-3H-cyclopenta[a]phenanthrene-2-bromide (compound 10). (Synthesis performed
by Nivedita Mahajani, Syracuse University)
To a solution of cyclohexenone 11 (0.100 g, 0.367 mmol) in DCM (1 mL) under argon at
0 °C, a solution of bromine (0.019 mL, 0.367 mmol) in DCM (1 mL) was added dropwise over 15
min. Triethylamine (0.087 mL, 0.623 mmol) was added and the resulting mixture was allowed to
warm to room temperature and stirred for another 1.5 hr before it was quenched with 1 M HCl.
The layers were separated and the organic layer was washed twice with sodium thiosulfate, dried
over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified
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by silica gel column chromatography (2% ethyl acetate/98% hexane), which afforded bromo enone
10 (0.103 g, 80%) as a white solid.
mp = 111-116 °C ; TLC Rf = 0.52 (10% ethyl acetate/90% hexanes); IR (thin film from
1
DCM) 2964, 2848, 1691, 1436, 954, 755 cm–1; [a]=>
< = +22.3 (c = 0.50, CHCl3); H NMR (400

MHz, CDCl3) δ 7.60 (s, 1H), 2.56-2.43 (m, 2H), 2.04-1.96 (m, 1H), 1.83-1.57 (m, 6H), 1.48-1.34
(m, 5H), 1.22-1.12 (m, 3H), 1.05 (s, 3H), 1.02-0.93 (m, 3H), 0.73 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 191.5, 158.9, 123.1, 54.4, 50.2, 44.2, 42.8, 41.0, 40.9, 40.2, 38.5, 35.7, 31.5, 27.2, 25.4,
21.4, 20.5, 17.6, 12.9. HRMS (ESI+) calculated for C19H28BrONa: 373.1137, Found: 373.1135.
Anal. calculated for C19H27BrO: C, 64.96; H, 7.75. Found: C, 64.72; H, 7.94.

(2R,5S,8S,9S,10S,13S,14S)–10,13–dimethyl–4,5,6,7,8,9,10,11,12,13,14,15,16,17–
tetradecahydro–3H–cyclopenta[a]phenanthren–3–one (compound 11). (Synthesis performed by
Nivedita Mahajani, Syracuse University)
A suspension of α-bromoketone 13 (0.600 g, 1.70 mmol), lithium bromide (0.884 g, 10.2
mmol), and lithium carbonate (0.752 g, 10.2 mmol) in DMF (6.6 mL) was heated to 80 °C. After
~18 hr the reaction mixture was cooled to room temperature and then poured over crushed ice. The
quenched reaction mixture was extracted with ethyl acetate (3 x 20 mL). The organic layers were
collected, combined, washed with cold water and brine, dried over sodium sulfate, filtered and
concentrated under reduced pressure. The residue was purified using silica gel column
chromatography (2% ethyl acetate/98% hexane), which afforded enone 11 (0.371 g, 80%) as a
white solid.
1
TLC Rf = 0.52 (10% ethyl acetate/90% hexane); [a]=>
< = +32.8 (c = 0.87, CHCl3); H NMR

(400 MHz, CDCl3) δ 7.13 (d, J = 10.2 Hz, 1H), 5.82 (dd, J = 10.2, 0.9 Hz, 1H), 2.34 (dd, J = 13.2,
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10.6 Hz, 1H), 2.21 (ddd, J = 17.6, 4.1, 0.9 Hz, 1H), 1.93–1.85 (m, 1H), 1.79–1.69 (m, 3H), 1.66–
1.51 (m, 3H), 1.49–1.33 (m, 5H), 1.18–1.10 (m, 3H), 1.02–0.90 (m, 6H), 0.71 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ 200.2, 158.6, 127.4, 54.5, 50.2, 44.3, 41.0, 40.9, 40.3, 39.1, 38.7, 36.1, 31.7,
27.7, 25.4, 21.3, 20.5, 17.6, 13.0. HRMS (ESI+) calculated for C19H28ONa: 295.2032, Found:
295.2030. Anal. calculated for C19H28O: C, 83.77; H, 10.36; Found: C, 83.83; H, 10.49.
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Figure 3.13 1H and 13C NMR spectra for compounds 9-11. (a) 1H NMR spectrum and (b) 13C
NMR spectrum for compound 9. (c) 1H NMR spectrum and (d) 13C NMR spectrum for
compound 10. (e) 1H NMR spectrum and (f) 13C NMR spectrum for compound 11. Reprinted
with permission from reference 1. © 2017, American Chemical Society.
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Chapter 4: Mutagenesis studies to locate functionally essential residues within hGOAT
Initial design and creation of hGOAT mutant constructs was performed in collaboration with
Rosemary Loftus, a Hougland research group Master’s student. Cloning of hGOAT_DC_1-4,
hGOAT_DC_1-5/6, hGOAT_DC_1-5/6,9-11, and hGOAT_DC_9-11 into the pFastBacDual
vector and activity screening and expression analysis of the resulting enzymes were performed in
part by Michael Aiduk.
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4.1 Introduction
Despite ongoing studies since its discovery in 2008,1, 2 many aspects of GOAT structure
and function remain undefined. As indicated by its initial assignment as the fourth member of the
MBOAT enzyme superfamily, the sequence of GOAT reveals homology with other MBOAT
family members with the C-terminus of GOAT comprising the conserved “MBOAT domain.”3
Two residues within this domain are highly conserved across MBOAT family members and
potentially implicated in catalysis: asparagine 307 (N307), which is highly conserved, and
histidine 338 (H338), which is absolutely conserved.3 Mutation of either of these residues within
GOAT abolishes activity.1, 2 Mutation of the conserved asparagine/aspartate residue results in a
complete loss of activity in Hhat,4, 5 but has been shown to have no effect on PORCN activity.6, 7
Conversely, mutation of the conserved histidine results in complete loss of activity in PORCN,6-8
but only a moderate reduction of activity in Hhat.4, 5, 9 Although H338 and N307 are implicated in
GOAT catalysis based on conservation and mutational analysis, the active site and catalytic
mechanism of GOAT remain undefined.
As an integral membrane protein, GOAT has proven resistant to purification protocols that
maintain enzymatic activity, preventing structural studies of the enzyme.10 In 2013, Taylor and
coworkers determined GOAT’s structural topology within the ER membrane using selective
permeabilization and epitope tag detection.11 Bioinformatics analysis predicted GOAT contains
12 transmembrane helices. Using mouse GOAT constructs containing N-terminal, C-terminal, or
internal epitope tags placed between the predicted helices followed by selective membrane
permeabilization, the loops between helices were assigned to either the lumen of the endoplasmic
reticulum or the cytoplasm. The final topology of GOAT was determined to contain 11
transmembrane helices and one re-entrant loop, with the N-terminus residing in the lumen and the
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C-terminus in the cytoplasm. Interestingly, this topology predicted that N307 and H338 were
located on opposite sides of the membrane, indicating that both could not be directly involved in
the GOAT active site.
After the publication of GOAT’s topology, the topology of Hhat was reported by two
independent groups.5, 12 Using selective permeabilization and immunofluorescence, the C-terminal
two-thirds of Hhat was shown to have remarkably similar topology to that of GOAT, with the
invariant histidine residing in the lumen and the conserved aspartate (equivalent to N307 in
GOAT) residing in a cytosolic loop,5, 12 providing further support of this topological model as an
important feature of the MBOAT family enzymes.
In the absence of structural information, mutagenesis of specific residues within GOAT
can provide information about the enzyme’s requirements for ghrelin acylation. Using the fact that
a serine hydroxyl within ghrelin is acylated as a guide for our mutagenesis campaign, we evaluated
potential mechanisms GOAT may employ to catalyze this acylation, based on known mechanisms
of other enzymes. We hypothesize GOAT employs a general base to activate the serine 3 hydroxyl
of ghrelin to act as a nucleophile. Classic serine proteases such as chymotrypsin or subtilisin
contain a catalytic triad in which a serine hydroxyl acts as the nucleophile and a histidine acts as a
general base to activate the serine, with an aspartate stabilizing the conjugate acid of histidine.13
Glycerol phosphate acyltransferases (GPATs) contain a conserved HX4D motif,14 with the
histidine and aspartate forming an ion pair to activate a hydroxyl of the glycerol 3-phosphate
substrate.15 In addition to aspartate (D) and histidine (H), enzymes can also use glutamate (E) or a
metal-bound water molecule/hydroxyl as a general base, with catalytic metals most frequently
coordinated by cysteine (C), aspartate (D), glutamate (E), or histidine (H).
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To identify functionally essential residues within GOAT, hGOAT variants containing

single-site mutations were designed and expressed. Residues for mutation were selected based on
the following criteria: 1) the residue can act as a general base or metal ligand (H, D, E, or C); 2)
the residue was within the conserved C-terminal MBOAT domain of the enzyme; and 3) the
residue was conserved across multiple species. Fifteen residues within hGOAT met this criteria
(Figure 4.1), and primers were designed to mutate these positions to either alanine (A) or a
structurally conservative residue (phenylalanine, F, for H; asparagine, N, for D; glutamine, Q, for
E; and serine, S, for C). Although it does not strictly meet these criteria, the highly conserved N307
was also mutated. These variants were expressed and screened for activity to determine which of
these sixteen residues were required for ghrelin acylation.
As described in Chapter 3, there is recent evidence that hGOAT contains at least one
functionally required cysteine residue based on inhibition by NEM and synthetic triterpenoids.16
Therefore, in addition to mutations targeting potential general bases, we also developed a series of
hGOAT mutant variants to determine the role of each of the sixteen cysteine residues within
hGOAT. A summary of this work is included herein, with complete characterization of the hGOAT
cysteine mutants an ongoing research project within the Hougland laboratory.
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Figure 4.1 Clustal Omega alignment of GOAT sequences from multiple species. Residues
selected for mutagenesis within hGOAT are highlighted in red.
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4.2   Results
Mutations targeting potential catalytic bases
Sixteen residues within hGOAT were selected for mutagenesis (Figure 4.1). Mutagenesis
primers were designed to mutate each position to alanine (Table 4.1), resulting in sixteen variants
of hGOAT-HA-FLAG-His6 within the pFastBacDual vector. The hGOAT gene was transposed
into bacmid DNA using the Bac-to-Bac expression system (Invitrogen). Purified bacmid was
transfected into Sf9 insect cells to generate baculovirus, which was used to infect Sf9 cells for
expression of hGOAT. Expressed hGOAT variants were obtained as enriched microsomal fraction
from insect cells through fractional ultracentrifugation. Expression of each hGOAT variant
containing a single-site alanine mutation was determined by SDS-PAGE and immunoblotting
(Western blotting) against the FLAG epitope tag. Successful hGOAT-HA-FLAG-His6 expression
was supported by the presence of a band at ~55 kDa, which was observed for all alanine mutants
except for E281A, E282A, and D289A (Figure 4.2).
Activity of each mutant variant was determined using a fluorescently-labeled ghrelin
mimetic substrate, GSSFLCAcDan, monitoring octanoylation by an increase in retention time on
reverse-phase HPLC.17 Mutation of seven residues to alanine resulted in complete loss of
observable activity (Figure 4.3). Of these seven inactive variants, expression of E282A was not
confirmed by Western blot, leaving open the possibility that the lack of activity arises from lack
of enzyme expression rather than loss of a functionally required residue. A peak at 12.5 minutes,
corresponding to the octanoylated peptide,17 was observed for the H258A, D262A, E281A,
D287A, D289A, E294A, H297A, H341A, and H362A mutants, indicating that these residues are
not functionally required for catalysis (Figure 4.3).
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D234A
C235A
H258A
D262A
D263A
E281A
E282A
D287A
D289A
E294A
H297A
N307A
H338A
H341A
D358A
H362A

Forward: 5’-GCCGGACTGACTGCTTGCCAGCAATTCGAATG-3’
Reverse: 5'-CATTCGAATTGCTGGCAAGCAGTCAGTCCGGC-3'
Forward: 5'-GGAGCCGGACTGACTGATGCCCAGCAATTCGAATG-3'
Reverse: 5'-CATTCGAATTGCTGGGCATCAGTCAGTCCGGCTCC-3'
Forward: 5'-GCTGACCTACTACTCAGCCTGGATCCTCGACG-3'
Reverse: 5'-CGTCGAGGATCCAGGCTGAGTAGTAGGTCAGC-3'
Forward: 5'-CACACTGGATCCTCGCCGATTCGCTCTTGC-3'
Reverse: 5'-GCAAGAGCGAATCGGCGAGGATCCAGTGTG-3'
Forward: 5'-CTGGATCCTCGACGCTTCGCTCTTGCACG-3'
Reverse: 5'-CGTGCAAGAGCGAAGCGTCGAGGATCCAG-3'
Forward: 5'-GACAGTCACCAGGAGCGGAAGGTTACGTTCC-3'
Reverse: 5'-GGAACGTAACCTTCCGCTCCTGGTGACTGTC-3'
Forward: 5'-GTCACCAGGAGAGGCAGGTTACGTTCCTG-3'
Reverse: 5'-CAGGAACGTAACCTGCCTCTCCTGGTGAC-3'
Forward: 5'-GGTTACGTTCCTGCCGCTGATATCTGGACC -3'
Reverse: 5'-GGTCCAGATATCAGCGGCAGGAACGTAACC-3'
Forward: 5'-CGTTCCTGACGCTGCTATCTGGACCCTGG-3'
Reverse: 5'-CCAGGGTCCAGATAGCAGCGTCAGGAACG-3'
Forward: 5'-GATATCTGGACCCTGGCAAGGACTCACAGAATC-3'
Reverse: 5'-GATTCTGTGAGTCCTTGCCAGGGTCCAGATATC-3'
Forward: 5'-CCCTGGAAAGGACTGCCAGAATCTCGGTCTTC-3'
Reverse: 5'-GAAGACCGAGATTCTGGCAGTCCTTTCCAGGG-3'
Forward: 5'-CTCCCGTAAGTGGGCCCAAAGCACTGCTCGC-3'
Reverse: 5'-GCGAGCAGTGCTTTGGGCCCACTTACGGGAG-3'
Forward: 5'-CAGCTTGGTGGGCCGGACTGCACCCTGG-3'
Reverse: 5'-CCAGGGTGCAGTCCGGCCCACCAAGCTG-3'
Forward: 5'-GCACGGACTGGCCCCTGGACAGGTTTTCGG-3'
Reverse: 5'-CCGAAAACCTGTCCAGGGGCCAGTCCGTGC-3'
Forward: 5'-GTTATGGTGGAGGCCGCCTACCTGATCCAC-3'
Reverse: 5'-GTGGATCAGGTAGGCGGCCTCCACCATAAC-3'
Forward: 5'-GCCGACTACCTGATCGCCTCCTTCGCTAACGAG-3'
Reverse: 5'-CTCGTTAGCGAAGGAGGCGATCAGGTAGTCGGC-3'

Table 4.1 Forward and reverse mutagenesis primers used to make the indicated mutations to
alanine within hGOAT.
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Figure 4.2 Expression analysis by Western blot for hGOAT mutant variants containing alanine
and conservative mutations, using a C-terminal FLAG epitope tag on all variants. (a)
Expression of H258A, C235A, C235S, and sCys supported by a band at ~55 kDa. No bands
were present for empty vector microsomal fraction. (b) Expression of D262A, H341A, H362A,
and H338A supported by the presence of a band at ~55 kDa. Nonspecific bands just above 55
kDa were present in all samples, including empty vector and uninfected microsomal fraction.
(c) Expression of D262A, D263A, and E294A supported by presence of a band at ~55 kDa.
Nonspecific bands just above 55 kDa were present in all samples, including empty vector
microsomal fraction. (d) Expression of E294A, H338A, H341A, D358A, and H362A supported
by the presence of a band at ~55 kDa. Nonspecific bands were present in all samples, including
empty vector and uninfected microsomal fraction. (e) Expression of D234A and C235A
supported by the presence of a band at ~55 kDa. No bands were present for empty vector
microsomal fraction. (f) Expression of N307A and D287A supported by the presence of a band
at ~55 kDa. No bands were seen for a His-tagged hGOAT variant, which does not contain the
FLAG epitope. (g) Expression of H338F supported by the presence of a band at ~55 kDa.
Nonspecific bands were seen in all samples, including empty vector microsomal fraction. (h)
Expression of D289A and H341A supported by the presence of a band ~55 kDa. No bands were
seen in uninfected microsomal fraction.
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(c)
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Figure 4.3 Activity screening of hGOAT alanine mutations probing for potential general bases.
(a) Chromatograms showing GSSFLCAcDan reaction with WT and mutant hGOAT variants,
with peptide substrate eluting at ~6 minutes and octanoylated peptide product eluting at ~12
minutes: WT, magenta; N307A, red; H297A, orange; D289A, yellow; E282A, green; C235A,
blue; D234A, purple; negative control with no acyl donor, gray. (b) Chromatograms showing
GSSFLCAcDan reaction with WT and mutant hGOAT variants, with peptide substrate eluting at
~6 minutes and octanoylated peptide product eluting at ~12 minutes: WT, magenta; H362, red;
D358A, orange; H341, green; H338A, blue; E294A, purple; negative control, gray. (c)
Chromatograms showing GSSFLCAcDan reaction with WT and mutant hGOAT variants, with
peptide substrate eluting at ~6 minutes and octanoylated peptide product eluting at ~12 minutes:
WT, magenta; D287A, orange; D262A, blue; negative control, gray. Sets of chromatograms are
grouped by reactions performed in parallel. (d) Summary of activity of each hGOAT alanine
mutant variant, normalized to the WT enzyme activity run side-by-side.
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For positions which resulted in a complete loss of activity when mutated to alanine, primers

were designed for a conservative mutation (Table 4.2). Aspartates (D) were mutated to asparagine
(N), glutamates (E) to glutamines (Q), histidines (H) to phenylalanine (F), and cysteine (C) to
serine (S). These mutations maintain size, structure, and polarity of the natural side chains, but still
remove general base capabilities. As for the alanine mutations, expression of conservative hGOAT
mutants was supported by Western blot for the C235S and H338F mutants (Figure 4.2a, g). Ghrelin
acylation activity was observed with the E282Q mutant, indicating that this residue is not required
for ghrelin acylation, but no evidence for octanoylation activity was observed for any of the other
conservative hGOAT mutants (Figure 4.4).

Mutations targeting cysteine residues
Based on the susceptibility of hGOAT to cysteine-modifying inhibitors such as the CDDO
derivatives and NEM (Chapter 3),16 we hypothesized that a cysteine residue within the enzyme
may be involved in the ghrelin acylation mechanism. Mutation of C235 to either alanine or serine
leads to a complete loss of hGOAT acylation activity. To assess whether this is the only
functionally required cysteine, we designed a single cysteine hGOAT mutant variant
(hGOAT_sCys), in which fifteen of the sixteen cysteine residues within hGOAT were mutated to
alanine leaving only C235 intact. Expression of this hGOAT mutant was verified by Western blot
against the FLAG epitope tag (Figure 4.2a), but no activity was observed (Figure 4.5a).

	
  

141

D234N
C235S
D263N
E282Q
H338F
D358N

Forward: 5'-GGAGCCGGACTGACTAATTGCCAGCAATTCGAATGT-3'
Reverse: 5'-ACATTCGAATTGCTGGCAATTAGTCAGTCCGGCTCC-3'
Forward: 5'-GCCGGACTGACTGATAGCCAGCAATTCGAATGT-3'
Reverse: 5'-ACATTCGAATTGCTGGCTATCAGTCAGTCCGGC-3'
Forward: 5'-CTGGATCCTCGACAATTCGCTCTTGCACGCTG-3'
Reverse: 5'-CAGCGTGCAAGAGCGAATTGTCGAGGATCCAG-3'
Forward: 5'-CAGTCCCAGGAGAGCAAGGTTACGTTCCTGAC-3'
Reverse: 5'-GTCAGGAACGTAACCTTGCTCTCCTGGGACTG-3'
Forward: 5'-CTTTCTCAGCTTGGTGGTTCGGACTGCACCCTGGA-3'
Reverse: 5'-TCCAGGGTGCAGTCCGAACCACCAAGCTGAGAAAG-3'
Forward: 5'-GTTATGGTGGAGGCCAACTACCTGATCCA-3'
Reverse: 5'-TGGATCAGGTAGTTGGCCTCCACCATAAC-3'

Table 4.2 Forward and reverse mutagenesis primers used to make the indicated mutations to
structurally conserved residues within hGOAT.
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Figure 4.4 Activity screening of hGOAT conservative mutations probing for potential general
bases. Chromatograms showing GSSFLCAcDan reaction with WT and mutant hGOAT variants,
with peptide substrate eluting at ~6 minutes and octanoylated peptide product eluting at ~12
minutes: WT, magenta; D358N, red; H338F, orange; E282Q, yellow; D263N, green; C235S,
blue; D234N, purple; negative control with no acyl donor, gray. Reactions were run in parallel.
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Figure 4.5 Activity screening of hGOAT mutant variants probing the role of cysteines within
hGOAT. (a) Chromatograms showing GSSFLCAcDan reaction with WT and sCys hGOAT, with
peptide substrate eluting at ~6 minutes and octanoylated peptide product eluting at ~12 minutes:
WT, magenta; sCys, blue. (b) Chromatograms showing GSSFLCAcDan reaction with WT and
hGOAT_DC_H1-4, with peptide substrate eluting at ~6 minutes and octanoylated peptide
product eluting at ~12 minutes: WT, magenta; _DC_H1-4, blue. (c) Chromatograms showing
GSSFLCAcDan reaction with WT and hGOAT_DC variants, with peptide substrate eluting at ~6
minutes and octanoylated peptide product eluting at ~12 minutes: WT, magenta; DC_H1_9-11,
orange; DC_H1_1-5/6,9-11, green; DC_H1_1-5/6, blue. Sets of chromatograms are grouped by
reactions performed in parallel.
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Next we designed mutant variants of hGOAT in which all cysteines within enzyme

topological subdomains were mutated to serine (Figure 4.6a). All cysteines from the N-terminus
to the end of transmembrane (TM) helix 4 were mutated to serine in hGOAT_DC_H1-4; all
cysteines from the N-terminus to the end of the reentrant loop between TM helices 5 and 6 were
mutated in hGOAT_DC_H1-5/6; all cysteines within TM helices 9 and 11 were mutated in
hGOAT_DC_H9-11; and all cysteines except for those within TM helices 6 and 7 were mutated in
hGOAT_DC_H1-5/6,9-11. Expression of these hGOAT mutants was confirmed by Western blot
against a C-terminal FLAG epitope tag (Figure 4.6b, c). Of these four mutant variants, only
hGOAT_DC_H9-11 showed any observable activity in our in vitro enzyme assay indicating that
the cysteines within this region (C350, C409, C421, and C434) are not absolutely required for
activity (Figure 4.5b, c). Investigation into the role of individual cysteine residues within TM
helices 1-8 is an ongoing project. Primers have been designed to mutate each of these cysteines to
serines individually, and the activity of the resulting hGOAT mutant variants will reveal the
specific requirement of each cysteine residue.
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Figure 4.6 Design and expression analysis of hGOAT variants targeting cysteines within
topological subdomains. (a) Topological model of hGOAT with cysteines highlighted
corresponding to topological subdomains. Cysteines within subdomain spanning TM helices 1
– 4 are highlighted in red; cysteines within subdomain spanning TM helix 5 through the
reentrant loop are highlighted in blue; cysteines within subdomain spanning TM helices 6 – 8
are highlighted in yellow; cysteines within subdomain spanning TM helices 9 – 11 are
highlighted in green. The model was constructed by comparison to the experimentally
developed topology model for mouse GOAT using the Protter online server.11, 18 (b) Expression
of DC_H1-5/6, DC_H1-5/6,9-11, and DC_H9-11 supported by the presence of bands at ~55
kDa. No bands were seen in empty vector microsomal fraction. (c) Expression of several
preparations of DC_H1-4 supported by the presence of bands at ~55 kDa. Different preparations
correspond to different amounts of virus added to optimize expression of the enzyme.
Nonspecific bands just above 55 kDa were present in all samples, including empty vector
microsomal fraction.
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4.3 Discussion and conclusions
Mutagenesis studies described here have revealed a number of residues within the human
isoform of GOAT that are required for activity. Among these functionally required residues are
N307 and H338, which are conserved across MBOAT family enzymes3 and proposed to be
involved in catalysis, confirming previous findings by other groups’ investigations of the mouse
and human isoforms of the enzyme.1, 2 In addition to these conserved residues, we identified four
additional residues – D234, C235, D263, and D358 – that are required for hGOAT activity. No
activity was observed when these residues were mutated to either alanine or a structurally
conservative residue. Expression of the D234N, D263N, and D358N hGOAT mutants could not
be confirmed by Western blot, so the lack of activity with these constructs may be due to lack of
expression rather than loss of a functionally required residue. The effects of single-point mutations
on hGOAT acylation activity are summarized in Figure 4.7.
Mutation of all cysteines in hGOAT except for C235 to alanine results in complete loss of
activity, though expression of the enzyme was confirmed, indicating that C235 is not sufficient for
catalytic activity. The series of hGOAT mutants targeting cysteines within specific regions of the
enzymes demonstrated that at least one of the cysteines within TM helices 1 – 4 is required for
activity. Acylation activity is maintained when all four cysteines within TM helices 9 – 11 are
maintained, indicating that these residues are not functionally required.
The functional requirement for C235 and at least one other cysteine along with the
susceptibility of hGOAT to inhibition by NEM16 provide the first indication that an MBOAT
family member contains a functionally required cysteine. Hhat contains multiple palmitoylated
cysteines, but activity of variants with these cysteines mutated to alanine were not determined.5
PORCN also contains at least one palmitoylated cysteine residue, but mutation of this residue to
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alanine resulted in acylation activity similar to that of the WT enzyme.8 Determining the individual
contribution of each cysteine within helices 1 through 4 of hGOAT, as well as cysteines in helices
5 through 8, may illuminate their functional role in catalysis.
These mutagenesis studies constitute the first steps to locating the active site of hGOAT
and determining the catalytic mechanism for ghrelin acylation. H338 is a likely candidate for the
general base, given its conservation across species1, 11 and other MBOAT enzymes.3 Based on the
proposed topology of GOAT,11 H338 may be located near two other functionally required residues,
D234 and C235, opening the possibility that multiple residues in this region are involved in
catalysis. Ongoing studies, both in our research group and through collaborations, will use these
findings and future experiments to determine the structural and mechanistic basis for hGOATcatalyzed ghrelin acylation.
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Figure 4.7 Topological model of hGOAT. Residues which resulted in loss of activity when
mutated to either alanine or a structurally conservative residue are colored in red. Residues
which retained activity when mutated to alanine are colored in blue. E282, which either did not
express or resulted in loss of activity when mutated to alanine, but maintained activity when
mutated to glutamine, is colored in yellow. The model was constructed by comparison to the
experimentally developed topology model for mouse GOAT using the Protter online server.11,
18
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4.4 Materials and methods
General
Mutagenesis primers were synthesized by Integrated DNA Technologies (Coralville, IA),
and were dissolved in purified water prior to use, with concentrations determined by UV
absorbance at 260 nm. Genes for hGOAT_sCys, hGOAT_DC_H1-4, hGOAT_DC_H1-5/6,
hGOAT_DC_H1-5/6,9-11, and hGOAT_DC_H9-11 were synthesized Bio Basic Inc. (Markham,
ON, Canada) in the pUC57 vector and were dissolved in purified water prior to use. Methoxy
arachidonyl fluorophosphonate (MAFP) was purchased from Cayman Chemical (Ann Arbor, MI)
as a stock in methyl acetate and diluted in DMSO prior to use. Octanoyl coenzyme A (octanoyl
CoA) was purchased from Advent Bio (Downers Grove, IL) solubilized to 5 mM in 10 mM TrisHCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored at -80 °C. Acrylodan
(Anaspec) was solubilized in acetonitrile, with the stock concentration determined by absorbance
at 393 nm upon dilution into methanol (e = 18,483 M-1 cm-1 per manufacturer’s data sheet). The
GSSFLCNH2 peptide for fluorescent labeling with acrylodan was synthesized by Sigma-Genosys
in the Pep-screen format, and solubilized in 1:1 acetonitrile:H2O and stored at -80 °C. Peptide
concentration was determined by absorbance at 412 nm following reaction of the cysteine thiol
with 5,5’-dithiobis(2-nitrobenzoic acid) using e = 14,150 M-1 cm-1.19

Single site mutagenesis of hGOAT plasmid DNA
PCR mutagenesis reactions (50 µl total volume) contained 1x Pfu reaction buffer, 10 ng
pFastBacDual_MBOAT4i_HA/FLAG/His6 template DNA previously prepared in our lab, 125 ng
forward primer, 125 ng reverse primer, 20 µM dNTPs, and 1 µL (2.5 units) Pfu Turbo DNA
polymerase (Agilent). The thermocycler program for PCR mutagenesis proceeded as follows:

	
  

150

initial denaturation (94 °C, 5 min); 30 cycles of denaturation (94 °C, 30 s), annealing (56 °C, 1
min), and extension (68 °C, 2 min); final extension (68 °C, 5 min). 1 µL (20 units) of DpnI was
added and reactions were incubated at 37 °C for 1 hr. After Dpn1 digestion, 5 µL of the PCR
reaction mixture was transformed into 50 µL of chemically competent DH5α cells (Zymo
Research) followed by incubation on ice for 30 min. Transformed bacteria were spread on LBampicillin (100 µg/mL) plates and incubated at 37 °C overnight. Single colonies were then
inoculated into 5 mL LB media containing 100 µg/mL ampicillin in sterile culture tubes, which
were incubated at 37 °C overnight with shaking (225 rpm). Following overnight growth, plasmids
were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic) per
manufacturer’s instructions. Single site mutations were verified by DNA sequencing (Genewiz).

Construction of sCys hGOAT plasmid DNA
200 µg of DNA in pUC57 vector was transformed into 50 µL DH5α E. coli cells, and
incubated on ice for 20 min. The cells were then spread onto LB-ampicillin (100 µg/mL) plates
and incubated at 37 °C overnight. A single transformed colony was plucked and inoculated into a
5 mL LB culture containing 100 µg/mL ampicillin, and grown overnight at 37 °C with shaking
(225 rpm). Following growth, plasmids were purified from the culture using EZ-10 Spin Column
Plasmid DNA kit (Bio Basic) per manufacturer’s instructions. Plasmids were stored at -20 °C.
Genes were ligated into pFBD-hGOAT-HA/Flag/His6 DNA vector using EcoRI and XhoI
restriction sites. 3 µg pFBD-hGOAT-HA/Flag/His6 DNA was digested with 1 µL (20 units) EcoRI,
1 µL (20 units) XhoI, 2 µL buffer 4 (20 µL total volume), and 1 µg pUC57 mutant hGOAT DNA
was digested with 0.5 µL (10 units) EcoRI, 0.5 µL (10 units) XhoI, 2 µL buffer 4 (20 µL total
volume), and incubated at 37 °C for 2 h. Samples were then run on a 0.8% agarose gel at 110 V
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for ~1 h. The bands for the pFBD vector and the mutant hGOAT insert were each cut out and DNA
was purified using EZ-10 Gel Extraction kit (Bio Basic) per manufacturer’s instructions, and
concentrations were measured by UV absorbance at 260 nm.
Ligations were performed with 25 ng of vector DNA, 17 ng insert DNA, 10 µL quick ligase
buffer, and 1 µL Quick Ligase (total volume 10 µL) and incubated on ice for 5 min. 5 µL of ligation
reaction was added to 50 µL DH5α cells, followed by 30 min incubation on ice. Cells were spread
on LB-ampicillin (100 µg/mL) plates and incubated at 37 °C overnight. Single colonies were
inoculated into 5 mL LB cultures containing 100 µg/mL ampicillin and grown overnight at 37 °C
with shaking (225 rpm). Following overnight growth, plasmids were purified from cultures using
EZ-10 Spin Column Plasmid DNA kit (Bio Basic) per manufacturer’s instructions, and successful
ligation was confirmed by DNA sequencing (Genewiz).

Expression and enrichment of hGOAT mutant variants
Mutant hGOAT genes within the pFastBacDual vector were transformed into DH10Bac E.
coli cells to produce bacmid encoding the mutant hGOAT using the Bac-to-Bac expression system
(Invitrogen). Sf9 insect cells (5.0 x 108 cells in a 500 mL total culture volume) were infected with
hGOAT baculovirus at a multiplicity of infection of 10 followed by protein expression for 40 h at
28 °C shaking 150 rpm. Cells were harvested by centrifugation (500 x g, 5 min), and freezing the
pellet at -80 °C. The cell pellets were thawed on ice, resuspended in 25 mL lysis buffer [150 mM
NaCl, 50 mM Tris-HCl (pH 7.0), 1 mM sodium ethylenediamine tetraacetate (NaEDTA), 1 mM
dithiothreitol (DTT), complete protease inhibitor (Roche), 10 µg/mL pepstatin A, and 100 µM
bis(4-nitrophenyl)phosphate]. The resuspended cells were lysed with a Dounce homogenizer on
ice, followed by removal of cell debris by centrifugation (3,000 x g, 4 °C, 10 min). The microsomal
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fraction was then isolated by ultracentrifugation of the supernatant (100,000 x g, 4 °C, 1 hr). The
isolated microsomal fraction pellet was resuspended in 50 mM HEPES (pH 7.0) and stored in lowadhesion microcentrifuge tubes at -80 °C until use.

Peptide substrate fluorescent labeling
GSSFLCNH2 (300 µM) and acrylodan (500 µM) were dissolved in 500 µL 1:1 50 mM
HEPES (pH 7.8):acetonitrile, followed by incubation at room temperature in the dark for 18 hr
with shaking. Acrylodan-labeled peptide was purified by reverse phase HPLC (Zorbax Eclipse
XDB column, 9.4 x 250 mm) using an isocratic mobile phase of water containing 0.05%
trifluoroacetic acid (TFA) (65%) and acetonitrile (35%) flowing at 4.2 mL/min over 21 min).
Labeled peptide eluted around 8 min, monitoring UV absorbance at 360 nm. Collected fractions
containing labeled peptides were dried under vacuum at room temperature and resuspended in 1:1
acetonitrile:H2O, and labeling was confirmed by MALDI-TOF mass spectrometry (Bruker
Autoflex III, SUNY-ESF) using a matrix of saturated sinapinic acid in 0.1% TFA and 50 mM
ammonium phosphate. Concentration of acrylodanylated peptide was determined by absorbance
of acrylodan at 360 nm (e = 13,300 M-1 cm-1), and was stored at -80 °C.

hGOAT activity assays and analysis
Microsomal fraction form Sf9 cells expressing WT or mutant hGOAT were thawed on ice
and passed through an 18-gauge needle 10 times to homogenize the fraction. Assays were
performed with ~100 µg of membrane protein, as determined by a Bradford assay. The microsomal
fraction was preincubated with 1 µM MAFP in 50 mM HEPES (pH 7.0) for 30 minutes at room
temperature.20 Reactions were initiated with the addition of 500 µM octanoyl CoA and 1.5 µM
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fluorescently labeled ghrelin mimetic, GSSFLCAcDan, in a total volume of 50 µL, incubated for 3
hr at room temperature, and stopped with the addition of 50 µL of 20% acetic acid in isopropanol,
and solutions were clarified by protein precipitation with 16.7 µL of 20% trichloroacetic acid
(TCA) followed by centrifugation (1,000 x g, ~1 min). The supernatant was analyzed by reverse
phase HPLC.
Assay samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase column
(Zorbax Eclipse, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05% TFA to 63%
acetonitrile in 0.05% TFA over 14 min, followed by 100% acetonitrile for 10 min. Fluorescent
peptides were detected by fluorescence (lex = 360 nm, lem = 485 nm), with the unacylated peptide
eluting with a retention time of ~6 min and the octanoylated peptide product eluting with a
retention time of ~12 min. Chromatogram analysis and peak integration was performed using
Chemstation for LC (Agilent Technologies).

Confirmation of expression by Western blot
Microsomal fractions were thawed on ice and passed through an 18-guage needle ten times
to homogenize. Membrane protein concentration was determined by Bradford assay, and samples
for gel analysis were prepared to contain 50 µg protein, 1x sample buffer (0.33 M Tris HCl pH
6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT), and 50 mM HEPES pH 7.0 in a total volume of
45 µL. Samples were heated at 50.2 °C for 5 min, followed by incubation at room temperature for
15 min. Samples were loaded onto a 10% SDS-polyacrylamide protein gel, and gels were run at
120 V for 1.5 hr. Proteins were then transferred to a polyvinylidene fluoride membrane using a
Bio Rad Trans-Blot Turbo Transfer System at 1.3 A / 25 V for 30 min.
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The membrane was blocked with 5% nonfat milk for 3 hr at room temperature with gentle

rocking, and then incubated with the Flag antibody, OctA-probe-HRP rabbit polyclonal antibody
(Santa Cruz Biotechnologies), in 5% nonfat milk (1:200 dilution, 10 mL total volume) overnight
at 4 °C with gentle rocking. Proteins bearing the Flag epitope were detected using a
chemiluminescent substrate (Thermo Fischer Scientific) and imaged. hGOAT and hGOAT mutant
variants are detected by the presence of a band at ~55 kDa.

	
  

155

References
1.  

Yang, J.; Brown, M. S.; Liang, G.; Grishin, N. V.; Goldstein, J. L., Identification of the
acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell
2008, 132 (3), 387-96.

2.  

Gutierrez, J. A.; Solenberg, P. J.; Perkins, D. R.; Willency, J. A.; Knierman, M. D.; Jin, Z.;
Witcher, D. R.; Luo, S.; Onyia, J. E.; Hale, J. E., Ghrelin octanoylation mediated by an
orphan lipid transferase. Proceedings of the National Academy of Sciences USA 2008, 105
(17), 6320-5.

3.  

Hofmann, K., A superfamily of membrane-bound O-acyltransferases with implications for
Wnt signaling. Trends in Biochemical Sciences 2000, 25 (3), 111-2.

4.  

Buglino, J. A.; Resh, M. D., Identification of conserved regions and residues within
Hedgehog acyltransferase critical for palmitoylation of Sonic Hedgehog. PLoS One 2010, 5,
e11195.

5.  

Konitsiotis, A. D.; Jovanović, B.; Ciepla, P.; Spitaler, M.; Lanyon-Hogg, T.; Tate, E. W.;
Magee, A. I., Topological analysis of Hedgehog acyltransferase, a multipalmitoylated
transmembrane protein. Journal of Biological Chemistry 2015, 290, 3293-307.

6.  

Proffitt, K. D.; Virshup, D. M., Precise regulation of porcupine activity is required for
physiological Wnt signaling. Journal of Biological Chemistry 2012, 287 (41), 34167-78.

7.  

Rios-Esteves, J.; Haugen, B.; Resh, M. D., Identification of key residues and regions
important for porcupine-mediated Wnt acylation. Journal of Biological Chemistry 2014, 289,
17009-19.

8.  

Gao, X.; Hannoush, R. N., Single-cell imaging of Wnt palmitoylation by the acyltransferase
porcupine. Nature Chemical Biology 2014, 10, 61-8.

	
  
9.  

156
Buglino, J. A.; Resh, M. D., Hhat is a palmitoylacyltransferase with specificity for Npalmitoylation of Sonic Hedgehog. Journal of Biological Chemistry 2008, 283, 22076-88.

10.   Barnett, B. P.; Hwang, Y.; Taylor, M. S.; Kirchner, H.; Pfluger, P. T.; Bernard, V.; Lin, Y.y.; Bowers, E. M.; Mukherjee, C.; Song, W.-j.; Longo, P. A.; Leahy, D. J.; Hussain, M. A.;
Tschöp, M. H.; Boeke, J. D.; Cole, P. A., Glucose and weight control in mice with a designed
ghrelin O-acyltransferase inhibitor. Science 2010, 330 (6011), 1689-92.
11.   Taylor, M. S.; Ruch, T. R.; Hsiao, P.-Y.; Hwang, Y.; Zhang, P.; Dai, L.; Huang, C. R. L.;
Berndsen, C. E.; Kim, M.-S.; Pandey, A.; Wolberger, C.; Marmorstein, R.; Machamer, C.;
Boeke, J. B.; Cole, P. A., Architectural organization of the metabolic regulatory enzyme
ghrelin O-acyltransferase. Journal of Biological Chemistry 2013, 288 (45), 32211-28.
12.   Matevossian, A.; Resh, M. D., Membrane topology of Hedgehog acyltransferase. Journal of
Biological Chemistry 2015, 290, 2235-43.
13.   Hedstrom, L., Serine protease mechanism and specificity. Chemical Reviews 2002, 102,
4501-23.
14.   Heath, R. J.; Rock, C. O., A conserved histidine is essential for glycerolipid acyltransferase
Catalysis. Journal of Bacteriology 1998, 180 (6), 1425-30.
15.   Turnbull, A. P.; Rafferty, J. B.; Sedelnikova, S., E.; Slabas, A. R.; Schierer, T. P.; Kroon, J.
T. M.; Simon, J. W.; Fawcett, T.; Nishida, I.; Murata, N.; Rice, D. W., Analysis of the
structure, substrate specificity, and mechanism of squash glycerol-3-phosphate (1)acyltransferase. Structure 2001, 9, 347-353.
16.   McGovern-Gooch, K. R.; Mahajani, N. S.; Garagozzo, A.; Schramm, A. J.; Hannah, L. G.;
Sieburg, M. A.; Chisholm, J. D.; Hougland, J. L., Synthetic triterpenoid inhibition of human

	
  

157
ghrelin O-acyltransferase: The involvement of a functionally required cysteine provides
mechanistic insight into ghrelin acylation. Biochemistry 2017, 56, 919-31.

17.   Darling, J. E.; Prybolsky, E. P.; Sieburg, M.; Hougland, J. L., A fluorescent peptide substrate
facilitates investigation of ghrelin recognition and acylation by ghrelin O-acyltransferase.
Analytical Biochemistry 2013, 437, 68-76.
18.   Omasits, U.; Ahrens, C. H.; Müller, S.; Wollscheid, B., Protter: interactive protein feature
visualization and integration with experimental proteomic data. Bioinformatics 2014, 30 (6),
884-6.
19.   Riddles, P. W.; Blakely, R. L.; Zerner, B., Ellman's Reagent: 5,5'-dithiobis(2-nitrobenzoic
acid) - a reexamination. Analytical Biochemistry 1979, 94, 75-81.
20.   McGovern-Gooch, K. R.; Rodrigues, T.; Darling, J. E.; Sieburg, M. A.; Abizaid, A.;
Hougland, J. L., Ghrelin octanoylation is completely stabilized in biological samples by alkyl
fluorophosphonates. Endocrinology 2016, 157, 4330-8.

	
  

158

Chapter 5: Development of a fluorescence-based high-throughput assay for rapid
identification of GOAT inhibitors
5.1 Introduction
As described in Chapter 1, GOAT is an attractive target for the therapeutic modulation of
ghrelin signaling. Ghrelin is the only predicted substrate for GOAT within the human proteome,13

and its octanoylation is absolutely necessary for its binding and activation of GHSR1a.1 Although

antagonists and agonists of the GHSR1a receptor have been extensively studied,4, 5 and despite the
potential for GOAT inhibitors as a novel avenue for controlling ghrelin signaling, there are only a
small number of reported GOAT inhibitors.6-10 Only one GOAT inhibitor – GO-CoA-Tat – has
been reported to be effective in cell and animal studies.7, 11, 12
The lack of reported GOAT inhibitors is due in part to experimental limitations of GOAT
activity assays. Reported GOAT activity assays employing recombinantly expressed enzyme in
microsomal fraction have determined GOAT activity by the detection of radiolabeled octanoate
incorporation,6,

7, 13, 14

detection of acylated ghrelin by radiolabeled anti-ghrelin antiserum,15

modification and detection of octynoate incorporation,16 or detection of increased peptide
hydrophobicity by reverse phase HPLC.17 Each of these assays requires extensive work-up after
reaction completion, making the analysis of large quantities of reactions difficult and timeconsuming. There are currently no cell-based screening assays reported for identifying GOAT
inhibitors, unlike those established for its MBOAT relative PORCN.18
In our efforts to identify novel small-molecule inhibitors of hGOAT, we have utilized our
HPLC-based assay to screen a library of diverse small molecules from the NIH Developmental
Therapeutics Program. Through this screen, we successfully identified a class of synthetic
triterpenoids which covalently and reversibly inhibit hGOAT in the low micromolar range.10
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However, this screen has been relatively low-throughput, with only 478 compounds out of the
1,596-compound library screened since its acquisition by the Hougland laboratory in 2014.
Clearly, more efficient identification of potent GOAT inhibitors requires an assay amenable to
high-throughput screening.
An alternative method to potentially detect acylation of ghrelin involves the fluorescentlylabeled ghrelin peptide substrates already used in our lab. Acrylodan, an environmentally-sensitive
fluorophore, increases in fluorescence when in a hydrophobic environment.19-21 Octanoylation of
a peptide labeled with acrylodan should result in an increase of peptide fluorescence within the
reaction mixture, which could be detected without the need to separate reaction products.
Modification of the fluorescent peptide GOAT substrate previously reported by our research
group17 has enabled sufficient fluorescence enhancement of the octanoylated peptide to monitor
GOAT activity without separation by HPLC. Without the need for separation of reaction
components, this modified assay could be adapted to a high-throughput format using a 96-well
plate fluorescent plate reader. As a proof of principle, the NIH Clinical Collection (NCC) library
of small molecules was screened using this assay.
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5.2 Results
Development of a modified fluorescent ghrelin substrate
Previous attempts to monitor GOAT octanoylation activity by an increase in fluorescence
of the solvatochromic acrylodan fluorophore on the ghrelin mimetic substrate GSSFLCAcDan were
unsuccessful (K. McGovern-Gooch and J. Darling, unpublished data). Addition of the
fluorescently labeled GSSFLCAcDan substrate into microsomal fraction resulted in an increase in
fluorescence independent of the presence of GOAT or the addition of the octanoyl CoA acyl donor.
As this fluorescence enhancement was not dependent on GOAT activity, a likely explanation is
the acrylodan fluorescence increases due to partitioning of the fluorescent substrate into the
hydrophobic microsomal fraction.
One avenue for increasing the fluorescence signal upon peptide octanoylation would be
modification of the ghrelin substrate peptide to generate greater fluorescence enhancement upon
acylation. Improved expression conditions which lead to increased hGOAT activity and improved
product stability with the incorporation of MAFP22 led us to revisit exploration of a fluorescencebased assay with a novel peptide substrate.
Our standard ghrelin peptide substrate, GSSFLCAcDan, exhibits a modest increase in
fluorescence upon acylation of serine 3.17 In this peptide, the acylation site at S3 lies three amino
acids away from the acrylodan fluorophore. If possible, moving the fluorophore position closer to
the acylation site could lead to an increased fluorescence change due to proximity to the
hydrophobic octanoyl group. Incorporation of the acrylodan at serine 2 (GCAcDanSFLS) led to an
inactive substrate, with subsequent studies indicating a steric constraint at the S2 position.3, 17
However, hGOAT is tolerant to mutations of F4, modifying substrates with a wide range of amino
acids at this position, including those with large side chains such as tryptophan.3 Mutation of F4
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to a cysteine allows the incorporation of acrylodan at the residue directly adjacent to the acylation
site, leading to an even greater degree of fluorescence enhancement. This peptide, GSSCLS, was
successfully labeled with acrylodan as confirmed by MALDI-TOF (Figure 5.1a), and was
octanoylated when incubated with octanoyl CoA and hGOAT in our standard HPLC-based assay
(Figure 5.1b).

Development of a real-time fluorescence-based hGOAT activity assay
We next sought to determine whether acylation of GSSCAcDanLS substrate could be
detected by an increase in fluorescence on a fluorescent plate reader, and if so, determine the
optimal conditions for reaction monitoring. At a microsomal fraction concentration of 10% v/v (10
µL in a 100 µL reaction volume, corresponding to ~50 µg protein) and GSSCAcDanLS concentration
of 0.5 µM, an increase in fluorescence over a three-hour reaction time was seen in the presence,
but not the absence, of 500 µM octanoyl CoA (Figure 5.2). At higher concentrations of peptide,
nonspecific fluorescence enhancement was observed in the absence of octanoyl CoA, consistent
with fractionation of the fluorescent peptide into the lipid microsomes.
To confirm that the increase in fluorescence at low peptide concentrations was specific to
the acylation of the ghrelin substrate, we performed controls in which we included empty vector
microsomal fraction (which does not contain hGOAT) or a GOAT inhibitor [Dap3]octanoylghrelin(1-5)-NH2 (10 µM, IC50 ~30 nM) in the presence of 500 µM octanoyl CoA. In these
negative control reactions, there was no increase in fluorescence over the time course of
observation, similar to reactions performed in the absence of octanoyl CoA (Figure 5.3).
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Figure 5.1 Modified ghrelin peptide GSSCAcDanLS is a substrate of hGOAT. (a) MALDI-TOF
confirmation of acrylodan labeling of cysteine residue of GSSCLSNH2. Expected mass of
potassium adduct = 814.6 Da, observed mass = 817.1 Da. An external standard with an expected
mass of 1089.5 Da for the potassium adduct also displayed a mass difference of +2 Da,
indicating successful labeling of GSSCAcDanLS. (b) HPLC chromatogram of GSSCAcDanLS in
reaction buffer (blue trace) and reaction of GSSCAcDanLS with hGOAT and octanoyl CoA (red).
The unacylated peptide elutes with a retention time of ~4 minutes, and the octanoylated product
elutes with a retention time of ~10 minutes.
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Figure 5.2 Low peptide concentrations minimize non-specific fluorescence enhancement. (a)
Fluorescence of 2 µM GSSCAcDanLS increases to a similar degree in the presence (closed circles)
and absence (open circles) of octanoyl CoA over time when incubated with hGOAT microsomal
fraction, indicating that fluorescence enhancement is not specific to acylation of peptide under
these conditions. (b) Fluorescence of 0.5 µM GSSCAcDanLS increases in the presence of octanoyl
CoA (closed circles), but to a much lesser degree in the absence of octanoyl CoA (open circles)
when incubated with hGOAT microsomal fraction. Fluorescence enhancement is given as the
percent increase in fluorescence relative to fluorescence at time0, as described in the Methods
section.
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Figure 5.3 Fluorescence enhancement is specific to acylation of GSSCAcDanLS peptide. The
fluorescence of the peptide increases over the three-hour reaction time relative to the
fluorescence at time0 in the complete reaction (black bars). In the absence of octanoyl CoA
(blue bars), in the absence of hGOAT (red bars), or in the presence of a high concentration of
GOAT inhibitor [Dap3]octanoyl-ghrelin(1-5)NH26 (green bars), the fluorescence either
decreases over the course of the reaction or minimally increases. Reactions were performed in
duplicate, and change in fluorescence is given as the percent difference in fluorescence at three
hours relative to fluorescence at time0 as described in the Methods section.
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Application of real-time fluorescence-based hGOAT activity assay to screen the NCC library
As the fluorescence assay employing the GSSCAcDanLS substrate proved amenable to a
plate-based high-throughput format, we applied this assay to perform a screen of the NIH Clinical
Collection (NCC) library of small molecule compounds for hGOAT inhibitors. For initial
screening, each compound in the NCC was tested at 100 µM for inhibition of hGOAT activity. As
a positive inhibitor control, the CDDO-EA small molecule hGOAT inhibitor previously identified
by our laboratory with an IC50 of 8 ± 4 µM was included in the screen.10 CDDO-EA inhibits
hGOAT activity to a degree where no fluorescence increase is seen in this assay when present at
100 µM, similar to a negative control with octanoyl CoA absent from the reaction. For each of the
700 compounds of the NCC library, the percent change in fluorescence at 3 hours and the fold
inhibition was calculated. Compounds resulting in an overall reduction in fluorescence or a
calculated fold inhibition greater than 10 were assigned a fold inhibition of 10 as a lower limit.
Across the NCC library, the average fold inhibition was 2.6 ± 2.9 with 10.4% of the compounds
exhibiting fold inhibitions more than 2.5 standard deviations from the mean, all but one of which
had met the 10-fold inhibition upper limit (Figure 5.4). To complete investigation of this library
of compounds, they will be screened at lower concentrations. Those that inhibit hGOAT at lower
concentrations will be validated by inhibition against hGOAT in the HPLC-based activity assay,
which provides a precise measurement of both acyl peptide product and unacylated peptide
substrate.

	
  

166

Figure 5.4 NCC library screening for hGOAT inhibitory activity at 100 µM. Screening results
are presented as a histogram of the number of compounds exhibiting a specific fold inhibition,
with fold inhibition defined as the percent change in fluorescence of the vehicle reaction
divided by the percent change in fluorescence of the reaction containing a test compound. Tenfold inhibition was set as the upper limit, and results were binned by every 0.1% inhibition.
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5.3 Discussion and conclusions
Since the discovery of GOAT, biochemical investigations of ghrelin octanoylation by this
enzyme have been limited by the lack of versatile, robust assays. All reported in vitro GOAT
activity assays have required extensive workup following reaction completion6, 7, 13-17 limiting their
application to high-throughput formats. While Garner and Janda’s cat-ELCCA assay16 can be
performed in a 96-well plate and was used to screen for inhibitors,8 it requires several steps to
modify the acylated product for analysis, multiple washing steps, and requires specific specialized
reaction components. The rapid advancement of studies of ghrelin acylation by GOAT and
identification of GOAT inhibitors will be greatly aided by development of a “mix and measure”
assay for GOAT activity compatible with high-throughput screening.
To our knowledge, the GOAT activity assay described above is the first real-time GOAT
activity assay, requiring no post-reaction workup or developing steps prior to analysis. GOATcatalyzed acylation of the ghrelin peptide is detected by an increase in fluorescence of acrylodan.
Non-specific increases in fluorescence, which presumably arise from the partitioning of the peptide
into the hydrophobic microsomal fraction, can be minimized by using low peptide concentrations.
A negative control reaction (such as no acyl donor, using empty vector microsomal fraction, or
using an inactive GOAT mutant variant) should be run in parallel for each set of reactions. In
addition, the optimal volume of microsomal fraction may vary between different preparations of
enzyme, so a titration of microsomal fraction protein should be performed for each new preparation
of enzyme. As expression and purification protocols for GOAT improve, standardization across
enzyme preparations should address this current limitation.
The loss of fluorescence enhancement in the presence of a high concentration of a known
GOAT inhibitor (Figure 5.3) indicated this assay could be used to screen a library of small
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molecules for novel GOAT inhibitors. The NIH Clinical Collection library was screened using this
assay, with compounds tested at an initial concentration of 100 µM. Of the 700 compounds of this
library, 10.3% inhibited hGOAT by at least 10-fold as measured by the fluorescence enhancement
in the presence of the test compound compared to the fluorescence enhancement in the presence
of the DMSO vehicle. Though this is a relatively high hit rate for a library screen, the high
concentration for library compounds the primary screen was chosen to be inclusive given the
overall lack of known GOAT inhibitors. In subsequent library screening studies, stringency can
easily be increased by lowering the candidate compound concentration in the GOAT activity assay.
Looking forward towards development of new GOAT inhibitors, it is important to note that
the NCC library consists of compounds that have already progressed to clinical trials as potential
therapeutics. As such, the bioavailability of many of these compounds has already undergone some
level of optimization. However, as these compounds were developed to target a wide range of
diseases and disorders, they were likely optimized for activity against a molecular target other than
GOAT. Therefore, it is possible that GOAT inhibitors discovered out of this library may not exhibit
selectivity toward the enzyme in cell- or animal-based studies. However, the discovery of
compounds from this library that do inhibit GOAT – even if only at relatively high concentrations
– may help to explain or predict potential side effects of these drugs when taken for a condition
unrelated to ghrelin signaling. The CDDO-based small molecule hGOAT inhibitors10 described in
Chapter 3 are an example of this, as they have shown effects consistent with altered ghrelin
signaling such as improved glucose tolerance and reduced fat deposition,23-26 despite not developed
to target any part of the ghrelin-GOAT system.
The fluorescence-based GOAT activity assay described here is the first that detects
acylation of ghrelin in real time. The ability to apply this assay to a high-throughput format will
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accelerate the identification of new GOAT inhibitors. Although the ability to thoroughly
characterize inhibitors (including measurement of IC50 values and determining reversibility) using
this assay has not been established, this format can be used to quickly eliminate non-inhibiting
compounds when analyzing structure-activity parameters of new inhibitor classes. The rapid
identification of new small molecule GOAT inhibitors will accelerate the development of
compounds that inhibit ghrelin signaling in biological contexts.
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5.4 Materials and methods
Preparation of acrylodan labeled C4 substrate
The ghrelin peptide substrate GSSCLS-NH2 was purchased from Sigma-Aldrich in
Pepscreen format. The peptide concentration was determined by reaction of free cysteine thiol with
5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) and measurement of absorbance at 412 nm, using e
= 14,150 M-1cm-1.27 Concentration of acrylodan was measured by absorbance at 393 nm in
methanol, using e = 18,483 M-1 cm-1. Labeling reactions contained 300 µM peptide and 500 µM
acrylodan in 50 mM HEPES pH 7.0 in 1:1 acetonitrile : H2O, and were vortexed for 18 h at room
temperature in the dark.
The acrylodan labeled peptide was purified by HPLC with a C18 reverse phase column
(Zorbax Eclipse XBD column, 9.4 x 250 mm) using a gradient of 2% acetonitrile in 0.05% TFA
to 100% acetonitrile over 30 min followed by 100% acetonitrile for 10 min. Labeled peptides were
monitored by absorbance at 360 nm, and eluted at a retention time of approximately 14 min.
Collected fractions containing labeled peptide were dried under vacuum for 10 hr at room
temperature in the dark, and resuspended in 50% acetonitrile in H2O. Acrylodan labeling was
confirmed by MALDI using α-cyano-4-hydroxycinnamic acid (CHCA) matrix using GSSCLS(PEG)2-K-biotin with a theoretical mass of 1089.5 Da as an external standard for calibration. The
concentration of labeled peptide was determined by absorbance at 360 nm in water, using e =
13,300 M-1 cm-1.17

Expression of hGOAT enzyme
Expression of hGOAT was performed using baculovirus encoding the hGOAT gene with
a multiplicity of infection (MOI) of 5 virus pfu/cell. For a 50 mL expression culture, 150 mL sterile
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culture flasks were seeded with 1.0 x 108 Sf9 cells and P2 virus in 1:1 Sf900 : Insectagro media
(Thermo Fisher and Corning, respectively), in a total volume of 50 mL. Expression cultures were
incubated for 40 hr at 28 °C with shaking at 150 rpm. Following incubation, expression cultures
were harvested by centrifugation (500 x g, 5 min, 4 °C), and the cell pellet was resuspended in 2.5
mL of lysis buffer containing 50 mM Tris-HCl pH 7.0, 150 mM NaCl, 1 mM NaEDTA, 1 mM
DTT, 0.01 µg/mL pepstatin A, 10 µM bis-4- nitrophenylphosphate, and 1 mini Roche protease
inhibitor cocktail tablet per 10 mL of buffer. The cells were then lysed and homogenized with a
Dounce homogenizer on ice, using 20 strokes with a small pestle and 20 strokes with a large pestle.
Intact cells and debris were removed by centrifugation (3,000 x g, 5 min, 4 °C). The microsomal
fraction was then isolated by centrifuging the supernatant (100,000 x g, 1 h, 4 °C). The microsomal
fraction pellet was solubilized in 50 mM HEPES pH 7.0 (4 µL/mg of pellet), and was stored in
100 µL aliquots at -80 °C.

Fluorescent plate reader library screen
Reactions contained 10 µL (~50 µg, as determined by Bradford assay) microsomal fraction
containing hGOAT, 1 µM MAFP, 100 µM test compound or equal volume of DMSO (1 µL), 500
µM octanoyl CoA, and 0.25 µM GSSCAcDanLS substrate in 50 mM HEPES (pH 7.0) in a total
volume of 100 µL in 96-well black low-adhesion polystyrene plates (Corning 3650). The
microsomal fraction was homogenized by passing through an 18-gauge needle 10 times, and was
preincubated with MAFP and the test compound in reaction buffer for 30 min at room temperature
in the 96-well plate before reactions were initiated with the addition of octanoyl CoA and peptide
substrate using a multichannel pipettor. Immediately following the addition of the peptide
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substrate, the fluorescence of each reaction was measured (lex 360 nm, lem 485 nm) on a
fluorescent plate reader (BioTek Synergy H1 Hybrid Reader) every 30 minutes for 3 hours.
GOAT activity was determined by calculating the percent change in fluorescence for each
time point measured using equation 1:
(1)

% change=

Fl- Flt0
Flt0

where Fl is the fluorescence measured at each time point, and Flt0 is the fluorescence at time 0.
Inhibitory activity was determined for each compound by calculating the fold inhibition relative
to DMSO controls using equation 2:
(2)

Fold inhibition =

average	
  %	
  change	
  at	
  3	
  h	
  of	
  DMSO	
  controls
%	
  change	
  at	
  3	
  h	
  in	
  presence	
  of	
  compound
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Chapter 6: Conclusions and future directions

Ghrelin signaling is an intriguing and important pathway with implications in diseases
ranging from type II diabetes to addiction.1-5 Despite extensive research into ghrelin’s
physiological roles since its discovery,6 many aspects of ghrelin signaling remain unclear including
the octanoylation of ghrelin by GOAT. The mechanism of GOAT catalysis is unknown, as are the
specific residues involved in substrate binding and catalysis. Given the importance of fully
understanding ghrelin signaling, as well as the unique nature of O-octanoylation, our work in the
Hougland laboratory aims to determine the mechanism of ghrelin acylation by GOAT, discover
how GOAT activity can be modulated through inhibition and/or agonism, and develop new tools
to study GOAT activity. The work in this thesis has made progress toward each of those goals:
several residues within hGOAT have been shown to be essential for ghrelin acylation activity, a
new class of small molecule hGOAT inhibitors has been discovered, and modifications to our in
vitro GOAT activity assay have been made which improve product stability and enable highthroughput screening.

6.1 Future inhibitor discovery and development
We have described a new class of hGOAT inhibitors which act through the covalent
modification of a cysteine residue within the enzyme.7 These CDDO derivatives and associated
compounds are only the second class of small molecule GOAT inhibitors to be reported in the
literature, and the first inhibitors which do not feature a lipid chain mimicking the octanoyl group
of acylated ghrelin.8 These new inhibitors, featuring a synthetic triterpenoid scaffold and an
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electrophilic a-cyanoenone, inhibit hGOAT in our in vitro enzyme activity assay with IC50 values
in the low micromolar range.
While the discovery of these cysteine-modifying hGOAT inhibitors provided valuable
information regarding the possibility of a cysteine residue involved in catalysis, their ability to
inhibit GOAT in cell-based assays has not been conclusively established. CDDO derivatives
including those that inhibit hGOAT have been shown to have several other biological targets,9 and
a clinical trial evaluating CDDO-Me as a treatment for chronic kidney disease was terminated due
to deleterious cardiovascular events.10 Therefore, these would not be selective for GOAT without
further optimization. Subsequent evaluation of patients taking part in the CDDO-Me clinical trial
revealed that specific risk factors for heart failure predicted the deleterious cardiovascular effects
leading to termination of the study, and thus should be used as exclusion criteria in future clinical
trials.11 This study and others evaluating CDDO derivatives have reported side effects consistent
with altered ghrelin signaling,10, 12-14 establishing that these drugs may still be useful therapeutics
targeting GOAT, as long as the effects of other targets can be accounted for.
While currently the best characterized example of a small molecule GOAT inhibitor
identified from a library screen in our work, CDDO-Im was just one of several hits from the initial
screen of the Diversity Set IV library. The structure-activity parameters of another small molecule
from this library are currently being analyzed in our laboratory in collaboration with the Chisholm
laboratory. The initial hit compound has an IC50 in the mid-micromolar range in our in vitro
hGOAT activity assay, and following a full structure-activity analysis it will be exciting to
determine the ability of this new class of inhibitors to inhibit ghrelin acylation in a cellular context.
In separate studies, other researchers in the Hougland laboratory are working to develop
new peptide-based hGOAT inhibitors. Previous work in our lab determined structural elements of
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ghrelin’s N-terminal residues important for recognition and modification by hGOAT.15,

16

Expanding upon studies establishing that mimics of acylated ghrelin are potent GOAT inhibitors,17,
18

our lab has developed a panel of non-acylated peptides based on ghrelin’s N-terminus which

inhibit hGOAT in our in vitro enzyme activity assay in the nanomolar range. Structure-activity
analysis of these inhibitors has established functional groups involved in binding to the enzyme.
One of the biggest challenges in discovering and developing GOAT inhibitors lies in
inability to purify the enzyme in an active form.19 Assays studying GOAT activity and inhibition
are either cell-based or rely on enriched, but unpurified, microsomal fraction. As described in
Chapters 2 and 5, the incorporation of microsomal fraction into GOAT activity assays inherently
introduces additional components (liposomes and other membrane-associated proteins), that make
the application of GOAT assays to a high-throughput format difficult, preventing screens of large
libraries of small molecules for GOAT inhibitors. Ultimately, improved protocols for purification
of integral membrane proteins may enable the purification of GOAT, enabling the development of
better activity assays and possibly the determination of its structure within the ER membrane. An
accurate, high-resolution picture of the substrate binding sites and active site of GOAT will provide
valuable information about contact sites that may be exploited in the design or optimization of
potent, selective small molecule inhibitors.

6.2 Developing tools to efficiently investigate GOAT enzymatic activity
Biochemical studies of GOAT have been limited since its discovery by the lack of tools
for efficiently studying enzyme activity. Low levels of product conversion and assays requiring
extensive workup have prevented extensive enzymatic characterization or their application to high-
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throughput screening for inhibitors. We have made several improvements to the in vitro
fluorescence-based GOAT assay which resolve both of these limitations.
Alkyl fluorophosphonates such as MAFP inhibit non-specific esterases present in enriched
microsomal fraction used as the GOAT enzyme source in several reported GOAT activity
assays.15, 17, 19, 20 These esterases degrade the acylated ghrelin product of the GOAT reaction to the
unacylated peptide and inhibiting the esterases with MAFP allows for much greater product
conversion and longer reaction times.21 MAFP appears to inhibit a range of ghrelin-active
esterases, as it effectively protects acyl ghrelin and acyl ghrelin mimetic peptides from degradation
in microsomal fraction from insect cells, in HEK293FT cell lysate, and in rat blood plasma.
We have also developed a GOAT activity assay based on the fluorescence enhancement of
acrylodan-labeled ghrelin peptides upon acylation. This readout does not require separation of
reaction products, so GOAT activity can be analyzed in real time on a fluorescent plate reader. We
have shown that fluorescence enhancement is specific to ghrelin acylation, as the enhancement is
blocked by omitting octanoyl CoA or enzyme, and by treatment with both peptide-based product
mimetic and small molecule inhibitors. This new assay will allow for more rapid identification of
novel small molecule inhibitors of hGOAT through high-throughput screening of libraries.
Our lab is currently developing additional tools to study hGOAT-catalyzed ghrelin
acylation. The advancement of any GOAT inhibitor depends upon proven activity in cells. Toward
this end, a cell line is currently being developed to efficiently study the effects of potential GOAT
inhibitors in a biologically relevant context. A prostate cancer cell line expressing preproghrelin
and GOAT was shown to increase proliferation in response to treatment with ghrelin.22-24 Ghrelindependent proliferation of these cells may be an alternative readout for GOAT activity, which
would provide an orthogonal screening platform for GOAT inhibition.
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6.3 Determination of GOAT substrate binding sites and catalytic mechanism
As described in Chapter 4, locating the substrate binding sites and determining the
mechanisms for protein acylation remains an unmatched challenge for all members of the MBOAT
superfamily despite recent successes in experimentally determining GOAT and Hhat membrane
topologies.25-27 Through mutational analysis of hGOAT, we have determined several residues that
are required for ghrelin octanoylation activity. Some of these residues are candidates for the
general base we have proposed to be involved in activation of ghrelin’s serine 3 hydroxyl for
nucleophilic attack. There are also multiple cysteine residues that appear to be important for
activity, as mutation of cysteine 235 individually to either alanine or serine and mutation of the
five cysteine residues within transmembrane helices 1 – 4 of hGOAT to serine collectively results
in complete loss of enzyme activity. Mutant variants of hGOAT in which individual cysteines are
mutated to serine are currently being developed, and will help to determine specific residues which
may be involved in catalysis.
Moving forward, a number of avenues are being pursued to gain a structural understanding
of GOAT-catalyzed ghrelin acylation. In a collaboration between our lab and the Nangia
laboratory of the Biomedical and Chemical Engineering Department at Syracuse University,
computational modeling coupled with mutational analysis has determined a number of residues
within hGOAT that are predicted to be important for ghrelin acylation. These studies are beginning
to define domains within GOAT that are required for substrate binding, enzyme stability, and
catalysis.
In addition to mutational analysis based on individual residues, constructs consisting of a
conserved loop domain within hGOAT are also being expressed for biochemical and structural
characterization. A large cytosolic loop between transmembrane helices 7 and 8 is highly
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conserved between GOAT and Hhat, and contains the conserved and functionally essential N307
residue.25-27 Structural and biochemical characterization of this domain on its own will illuminate
its role in GOAT activity, and provide the first information regarding subdomain conformation
within GOAT.
Collectively, these studies will provide a comprehensive view of ghrelin acylation by
GOAT. Mutational analysis alone reveals residues which are required for enzyme activity, but in
conjunction with computational analyses, biophysical and structural studies, and bioinformatics
analysis across species, our lab may elucidate which of those functionally essential residues are
involved in enzyme stability, substrate binding, and catalysis.

6.4 Summary and future direction
We have made several advances in this work toward the study of ghrelin acylation by
hGOAT, including the discovery of a new class of small molecule inhibitors, the determination of
residues which are required for activity, and developments to our assay which improve sensitivity
and product stability and enable real-time monitoring of GOAT activity. As each of these projects
continue forward, progress in one area will inherently inform and help progress the others. For
instance, one ultimate goal of our lab’s work is to determine the mechanism by which GOAT
catalyzes ghrelin octanoylation. When the residues involved in binding to either the ghrelin peptide
or octanoyl CoA are determined, we may be better able to rationally design or optimize GOAT
inhibitors by exploiting these contacts. In addition, discoveries made in other MBOAT family
members – especially those that also acylate protein substrates, Hhat and PORCN – may help us
better understand those aspects in GOAT. Given the remarkable similarity between the topologies
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of Hhat and GOAT within the ER membrane,25-27 it seems likely that these enzymes employ similar
mechanisms and are susceptible to similar inhibitors.
Given ghrelin’s role in an ever-growing number of physiological processes and in diseases
such as diabetes and obesity, studies such as these are imperative to understanding the entire
picture of ghrelin activation and signaling within the body. These studies will also aid in
determining if and how pharmaceutical modulation of ghrelin signaling in vivo is a therapeutic
avenue for the treatment of these and other diseases. Ghrelin’s role in the body goes far beyond
that of a hunger-inducing ligand for the GHSR1a receptor. The “traditional” view of ghrelin
processing requires octanoylation by GOAT in the ER, and subsequent binding to GHSR1a to
induce its biological effects. Yet it is now known that unacylated ghrelin exerts its own biological
effects, prompting the questions: does unacylated ghrelin have its own unique receptor? And is the
hydrolysis of ghrelin to unacylated ghrelin independently regulated through a ghrelin esterase?
Several esterases have demonstrated in vitro activity against ghrelin28-31 but it is not known
whether ghrelin is specifically regulated through these enzymes in vivo. Another related question
is whether ghrelin acylation/deacylation is a dynamic process in the body, similar to the reversible
nature of palmitoylation.32 A recent study reported the localization of active GOAT within the
plasma membrane of mouse bone marrow adipocytes, suggesting that ghrelin can be acylated
directly at its target cells.33 Replication of this study in bone marrow adipocytes and other tissues
would lend weight to the idea that ghrelin acylation is dynamic, even after secretion from the cell.
With every new publication regarding ghrelin, the signaling pathway of this hormone
appears to be increasingly complex with many aspects remaining undefined. Determination of a
complete, accurate picture of the roles played by ghrelin in the body depends on the development
of tools to accurately study ghrelin expression, acylation, deacylation, and interactions with other
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biomolecules. Small molecules GOAT inhibitors such as the CDDO derivatives may serve as
clinically useful therapeutics for diseases such as diabetes, but they will also be used as
pharmacological tools to temporally control GOAT activity when studying ghrelin signaling in
cell or animal models. Improvements to GOAT activity assays described in this work will also aid
in the discovery of new, more potent, and more selective GOAT inhibitors, and may also be applied
to studying other aspects of the ghrelin signaling pathway, such as esterase-catalyzed deacylation
of ghrelin.
Mutational analysis of hGOAT, structure-activity analysis of hGOAT inhibitors, and
development of in vitro enzyme activity assays described in this work contribute to the ultimate
goal of understanding how GOAT catalyzes the octanoylation of ghrelin, an essential and largely
enigmatic step in ghrelin processing. Future work in the Hougland laboratory and others studying
GOAT may provide answers for the many questions still surrounding this enzyme and the other
aspects of the ghrelin signaling pathway.
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License date

May 10, 2017

Licensed Content Publisher

John Wiley and Sons

Licensed Content Publication

Angewandte Chemie International Edition

Licensed Content Title

cat-ELCCA: A Robust Method To Monitor the Fatty Acid
Acyltransferase Activity of Ghrelin O-Acyltransferase (GOAT)

Licensed Content Author

Amanda L. Garner,Kim D. Janda

Licensed Content Date

Sep 15, 2010

Licensed Content Pages

5

Type of use

Dissertation/Thesis

Requestor type

University/Academic

Format

Print and electronic

Portion

Figure/table

Number of figures/tables

1

Original Wiley figure/table
number(s)

Figure 3a

Will you be translating?

No

Title of your thesis /
dissertation

Enzymology and Inhibition of Ghrelin Acylation by Ghrelin OAcyltransferase

Expected completion date

Aug 2017

Expected size (number of
pages)

150

Requestor Location

Kayleigh R McGovern-Gooch
120 Newbury Hollow Lane
Apt 8
SYRACUSE, NY 13210
United States
Attn: Kayleigh R McGovern-Gooch

Publisher Tax ID

EU826007151

Billing Type

Invoice
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Billing Address

Kayleigh R McGovern-Gooch
120 Newbury Hollow Lane
Apt 8
SYRACUSE, NY 13210
United States
Attn: Kayleigh R McGovern-Gooch

Total

0.00 USD

Terms and Conditions

TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a"Wiley Company") or handled on behalf of a society with
which a Wiley Company has exclusive publishing rights in relation to a particular work
(collectively "WILEY"). By clicking "accept" in connection with completing this licensing
transaction, you agree that the following terms and conditions apply to this transaction (along
with the billing and payment terms and conditions established by the Copyright Clearance
Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened
your RightsLink account (these are available at any time at http://myaccount.copyright.com).
Terms and Conditions
•  

The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.

•  

You are hereby granted a personal, non-exclusive, non-sub licensable (on a standalone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a one-time
use only and limited to any maximum distribution number specified in the license. The
first instance of republication or reuse granted by this license must be completed
within two years of the date of the grant of this license (although copies prepared
before the end date may be distributed thereafter). The Wiley Materials shall not be
used in any other manner or for any other purpose, beyond what is granted in the
license. Permission is granted subject to an appropriate acknowledgement given to the
author, title of the material/book/journal and the publisher. You shall also duplicate the
copyright notice that appears in the Wiley publication in your use of the Wiley
Material. Permission is also granted on the understanding that nowhere in the text is a
previously published source acknowledged for all or part of this Wiley Material. Any
third party content is expressly excluded from this permission.

•  

With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
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clearing permission under the terms of the STM Permissions Guidelines only, the
terms of the license are extended to include subsequent editions and for editions
in other languages, provided such editions are for the work as a whole in situ and
does not involve the separate exploitation of the permitted figures or
extracts, You may not alter, remove or suppress in any manner any copyright,
trademark or other notices displayed by the Wiley Materials. You may not license,
rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials
on a stand-alone basis, or any of the rights granted to you hereunder to any other
person.
•  

The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you shall
not assert any such right, license or interest with respect thereto

•  

NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.

•  

WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.

•  

You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.

•  

IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
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WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
•  

Should any provision of this Agreement be held by a court of competent jurisdiction to
be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby.

•  

The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or excused
by either party unless such waiver or consent is in writing signed by the party granting
such waiver or consent. The waiver by or consent of a party to a breach of any
provision of this Agreement shall not operate or be construed as a waiver of or consent
to any other or subsequent breach by such other party.

•  

This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.

•  

Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.

•  

These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns.

•  

In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.

•  

WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
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•  

This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.

•  

This Agreement shall be governed by and construed in accordance with the laws of the
State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.

WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish open
access articles under the terms of the Creative Commons Attribution (CC BY) License only,
the subscription journals and a few of the Open Access Journals offer a choice of Creative
Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and nonCreative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online
Library http://olabout.wiley.com/WileyCDA/Section/id-410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1978-646-2777.
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OXFORD UNIVERSITY PRESS LICENSE
TERMS AND CONDITIONS
Jul 17, 2017

This Agreement between Kayleigh R McGovern ("You") and Oxford University Press
("Oxford University Press") consists of your license details and the terms and conditions
provided by Oxford University Press and Copyright Clearance Center.
License Number

4126570449633

License date

Jun 12, 2017

Licensed content
publisher

Oxford University Press

Licensed content
publication

Endocrinology

Licensed content
title

Ghrelin Octanoylation Is Completely Stabilized in Biological Samples by Alkyl
Fluorophosphonates

Licensed content
author

McGovern-Gooch, Kayleigh R.; Rodrigues, Trevor

Licensed content
date

Sep 13, 2016

Type of Use

Thesis/Dissertation

Institution name
Title of your work Enzymology and Inhibition of Ghrelin Acylation by Ghrelin O-Acyltransferase
Publisher of your n/a
work
Expected
publication date

Aug 2017

Permissions cost

0.00 USD

Value added tax

0.00 USD

Total

0.00 USD

Requestor
Location

Kayleigh R McGovern-Gooch
120 Newbury Hollow Lane
Apt 8
SYRACUSE, NY 13210
United States
Attn: Kayleigh R McGovern-Gooch
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Publisher Tax ID

GB125506730

Billing Type

Invoice

Billing Address

Kayleigh R McGovern-Gooch
120 Newbury Hollow Lane
Apt 8
SYRACUSE, NY 13210
United States
Attn: Kayleigh R McGovern-Gooch

Total

0.00 USD

Terms and Conditions

STANDARD TERMS AND CONDITIONS FOR REPRODUCTION OF MATERIAL
FROM AN OXFORD UNIVERSITY PRESS JOURNAL
1. Use of the material is restricted to the type of use specified in your order details.
2. This permission covers the use of the material in the English language in the following
territory: world. If you have requested additional permission to translate this material, the
terms and conditions of this reuse will be set out in clause 12.
3. This permission is limited to the particular use authorized in (1) above and does not allow
you to sanction its use elsewhere in any other format other than specified above, nor does it
apply to quotations, images, artistic works etc that have been reproduced from other sources
which may be part of the material to be used.
4. No alteration, omission or addition is made to the material without our written consent.
Permission must be re-cleared with Oxford University Press if/when you decide to reprint.
5. The following credit line appears wherever the material is used: author, title, journal, year,
volume, issue number, pagination, by permission of Oxford University Press or the sponsoring
society if the journal is a society journal. Where a journal is being published on behalf of a
learned society, the details of that society must be included in the credit line.
6. For the reproduction of a full article from an Oxford University Press journal for whatever
purpose, the corresponding author of the material concerned should be informed of the
proposed use. Contact details for the corresponding authors of all Oxford University Press
journal contact can be found alongside either the abstract or full text of the article concerned,
accessible from www.oxfordjournals.org Should there be a problem clearing these rights,
please contact journals.permissions@oup.com
7. If the credit line or acknowledgement in our publication indicates that any of the figures,
images or photos was reproduced, drawn or modified from an earlier source it will be
necessary for you to clear this permission with the original publisher as well. If this
permission has not been obtained, please note that this material cannot be included in your
publication/photocopies.
8. While you may exercise the rights licensed immediately upon issuance of the license at the
end of the licensing process for the transaction, provided that you have disclosed complete and
accurate details of your proposed use, no license is finally effective unless and until full
payment is received from you (either by Oxford University Press or by Copyright Clearance
Center (CCC)) as provided in CCC's Billing and Payment terms and conditions. If full
payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in the event that
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you breach any of these terms and conditions or any of CCC's Billing and Payment terms and
conditions, the license is automatically revoked and shall be void as if never granted. Use of
materials as described in a revoked license, as well as any use of the materials beyond the
scope of an unrevoked license, may constitute copyright infringement and Oxford University
Press reserves the right to take any and all action to protect its copyright in the materials.
9. This license is personal to you and may not be sublicensed, assigned or transferred by you
to any other person without Oxford University Press’s written permission.
10. Oxford University Press reserves all rights not specifically granted in the combination of
(i) the license details provided by you and accepted in the course of this licensing transaction,
(ii) these terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.
11. You hereby indemnify and agree to hold harmless Oxford University Press and CCC, and
their respective officers, directors, employs and agents, from and against any and all claims
arising out of your use of the licensed material other than as specifically authorized pursuant
to this license.
12. Other Terms and Conditions:
v1.4
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1978-646-2777.
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Title:

Synthetic Triterpenoid Inhibition of Human
Ghrelin O-Acyltransferase: The Involvement of a
Functionally Required Cysteine Provides
Mechanistic Insight into Ghrelin Acylation

Author:

Kayleigh R. McGovern-Gooch, Nivedita S.
Mahajani, Ariana Garagozzo, et al

Publication: Biochemistry
Publisher:

American Chemical Society

Date:

Feb 1, 2017

If you're a copyright.com
user, you can login to RightsLink
using your copyright.com credentials.
Already a RightsLink user or want
to learn more?

Copyright © 2017, American Chemical Society

PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:

§  
§  
§  
§  

§  

Permission is granted for your request in both print and electronic formats, and
translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your
publisher/graduate school.
Appropriate credit for the requested material should be given as follows: "Reprinted
(adapted) with permission from (COMPLETE REFERENCE CITATION).
Copyright (YEAR) American Chemical Society." Insert appropriate information in
place of the capitalized words.
One-time permission is granted only for the use specified in your request. No
additional uses are granted (such as derivative works or other editions). For any other
uses, please submit a new request.

Copyright © 2017 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. Terms and Conditions.
Comments? We would like to hear from you. E-mail us at customercare@copyright.com
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Kayleigh R. McGovern-Gooch
kmcgover@syr.edu
1307 Marlbrook Lane
Lansdale, PA 19446

Tel (cell): (518) 420-5935
Tel (lab): (315) 443-5912
Tel (fax): (315) 443-4070

Syracuse University
Department of Chemistry
Syracuse, NY 13244-4100

Education
Ph. D.

Department of Chemistry
Syracuse University, Syracuse, NY

Summer 2017
(anticipated)

M. Phil.

Department of Chemistry
Syracuse University, Syracuse, NY

2014

B. S.

Department of Chemistry
St. John’s University, Queens, NY

2012

Research Experience
2012-present

Enzymology and inhibition of ghrelin acylation by ghrelin
O-acyltransferase
Doctoral Dissertation, Syracuse University
Advisor: Prof. James L. Hougland

2010-2012

Investigation of interfacial free energy of aliphatic and
aromatic surfaces in aqueous solutions by atomic force
microscopy
Undergraduate Investigator, St. John’s University
Advisor: Prof. Joseph M. Serafin

Awards and Fellowships
2016

ACS Women Chemists Committee Travel Award, Eli Lily &
Company

2014

Nominated for Women in Science and Engineering Future
Professionals Program, Syracuse University

2012

Graduate Assistance in Areas of National Need Fellowship,
Syracuse University

2011

St. John’s College Gold Key Recipient, St. John’s University
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Publications
K. R. McGovern-Gooch, N. S. Mahajani, A. Garagozzo, A. J. Schramm, L. G. Hannah,
M. A. Sieburg, J. D. Chisholm, and J. L. Hougland
“Synthetic triterpenoid inhibition of human ghrelin O-acyltransferase: Involvement of a
functionally required cysteine provides mechanistic insight into ghrelin acylation.”
Biochemistry. 2017, 56(7):919-931
K. R. McGovern-Gooch, T. Rodrigues, J. E. Darling, M. A. Sieburg, A. Abizaid, and J.
L. Hougland
“Ghrelin octanoylation is completely stabilized in biological samples by alkyl
fluorophosphonates.”
Endocrinology. 2016, 157(11):4330-4338
K. R. McGovern, J. E. Darling, and J. L. Hougland
“Progress in small molecule and biologic therapeutics targeting ghrelin signaling.”
Mini Rev Med Chem. 2016, 16(6):465-480
K. R. McGovern-Gooch, J. E. Darling, J. L. Hougland
“A fluorescence-based high throughput assay to rapidly identify small molecule
inhibitors of ghrelin acylation by ghrelin O-acyltransferase”
In preparation
K. R. McGovern-Gooch, M. B. Campaña, R. L. Loftus, and J. L. Hougland
“Toward defining the ghrelin O-acyltransferase active site: Determination of functionally
essential residues within hGOAT”
In preparation

Teaching Experience
Spring 2017
Spring 2016

Teaching Assistant, Organic Chemistry II Recitation,
Syracuse University
Led students through organic chemistry problems
supplementing the course
Advisor: Prof. James Kallmerten

Fall 2015

Teaching Assistant, Organic Chemistry I Recitation,
Syracuse University
Led students through organic chemistry problems
supplementing the course
Advisor: Prof. James L. Hougland
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2014-2017

Undergraduate Research Mentor, Biochemistry, Syracuse
University
Mentored four undergraduate students in biochemical
laboratory techniques
Advisor: Prof. James L. Hougland

Spring 2015
Fall 2013

Teaching Assistant, General Chemistry Laboratory, Syracuse
University
Instructed laboratory experiments designed to reinforce and
supplement the course
Advisor: Gary Bonomo

Poster Presentations
August 2016

“Ghrelin acylation by ghrelin O-acyltransferase: Enzyme
mutagenesis studies and inhibitor library screening”
Kayleigh R. McGovern, Nivedita Mahajani, Anthony J. Schramm,
Ariana Garagozzo, John Chisholm, and James L. Hougland
252nd American Chemical Society National Meeting Philadelphia,
PA

July 2015

“Ghrelin acylation by human ghrelin O-acyltransferase: Enzyme
mutagenesis studies and inhibitor library screening”
Kayleigh R. McGovern, Anthony J. Schramm, Ariana Garagozzo,
and James L. Hougland
FASEB Science Research Conference for Protein Lipidation,
Signaling and Membrane Domains
Saxtons River, VT

June 2015

“Investigating human ghrelin O-acyltransferase: Functional studies
and inhibitor screening”
Kayleigh R. McGovern, Anthony J. Schramm, Ariana Garagozzo,
and James L. Hougland
American Chemical Society Northeast Regional Meeting
Ithaca, NY

May 2014

“Defining the catalytic machinery of hGOAT”
Kayleigh R. McGovern, Rosemary J. Loftus, and James L.
Hougland
Chemistry Graduate Student Symposium (SUNY-Buffalo),
Buffalo, NY

